FINAL REPORT
RELATIVE BIOAVAILABILITY OF ARSENIC
IN SOILS FROM THE VBI70 SITE
Stan W. Casteel, DVM, PhD, DABVT
Principal Investigator
Tim Evans, DVM
Margaret E. Dunsmore, BS
Co-Investigators
Veterinary Medical Diagnostic Laboratory
College of Veterinary Medicine
University of Missouri, Columbia
Columbia, Missouri
Christopher P. Weis, PhD, DABT
Study Design and Technical Advisor
Bonita Lavelle
Remedial Project Manager
US Environmental Protection Agency - Region 8
Denver, Colorado
William J. Brattin, PhD
Tracy L. Hammon, MS
Technical Consultants
Syracuse Research Corporation
Denver, Colorado
January 2001
-------
ACKNOWLEDGEMENTS
The work described in this report is the product of a team effort involving a number of people.
In particular, the authors would like to acknowledge the efforts and support of the following:
Dr. John Drexler at the University of Colorado, Boulder, performed the electron
microprobe and particle size analyses of the test materials.
Dr. Edward Hinderberger of L E T., Inc., Columbia, Missouri, provided prompt and
reliable chemical analysis of all of the samples for total arsenic concentrations.
VBI70 Arsenic RBA Final.doc
l
-------
EXECUTIVE SUMMARY
The gastrointestinal absorption of arsenic from soil samples collected from residential properties
at the Vasquez Boulevard and 1-70 (VBI70) Superfund site was measured using young swine.
Test materials include composite soil samples from five different residences with arsenic levels
ranging from 290 to 860 ppm. In addition, one sample was prepared by mixing clean site soil
(arsenic <10 ppm) with an arsenical herbicide (PAX) to yield a concentration of about 460 ppm.
Groups of animals (four animals per dose group) were given oral doses of reference material
(sodium arsenate) or test material twice a day for 12 days. Urine excreted by each animal was
collected on days 6-7, 8-9 and 10-11. The urinary excretion fraction (UEF) (the ratio of the
amount excreted per 48 hours divided by the dose given per 48 hours) was calculated for each
test material using linear regression analysis. The relative bioavailability (RBA) of arsenic in
test material compared to that in sodium arsenate (abbreviated NaAs) was calculated as:
UEF{test material)
UEF {NaAs)
The results are summarized below:
Test
Material
Description
Neighborhood
Arsenic
Cone, (ppm)
Relative Bioavailability
Best Est.
90% CI
TM1
Soil composite from impacted
residential property
Eastern
Swansea/Elyria
312
0.35
0.26-0.45
TM2
Soil composite from impacted
residential property
Western
Swansea/Elyria
983
0.45
0.38-0.52
TM3
Soil composite from impacted
residential property
Eastern Cole
390
0.36
0.31-0.42
TM4
Soil composite from impacted
residential property
Western Cole
813
0.21
0.17-0.25
TM5
Soil composite from impacted
residential property
Clayton
368
0.18
0.15-0.21
TM6
Clean site soil plus
added PAX
Swansea/Elyria
516
0.23
0.19-0.28
An estimate of the site-wide mean RBA value may be derived by combining the values across all
five site samples (TM1-TM5). Because of the inherent variability and uncertainty in the data,
the 95% UCL of the site-wide mean RBA value is recommended for use in calculation of human
risk from ingestion of arsenic in site soils. The results are shown below:
Statistic
Value
Mean
0.31
95% UCL
0.42
Based on a consideration of all available data, a final RBA value of 0.42 is recommended.
VBI70 Arsenic RBA Final.doc
11
-------
TABLE OF CONTENTS
EXECUTIVE SUMMARY ii
1.0 INTRODUCTION 1
2.0 STUDY DESIGN 3
2.1 Test Materials 3
2.2 Experimental Animals 5
2.3 Diet 5
2.4 Dosing 6
2.5 Collection and Preparation of Samples 6
2.6 Arsenic Analysis 6
3.0 DATA ANALYSIS 9
4.0 RESULTS 11
4.1 Urinary Excretion Fractions 11
4.2 Calculation of Relative Bioavailability 12
4.3 Fecal Excretion and Mass Balance 12
4.4 In Vitro Bioaccessability 13
5.0 DISCI SSION AM) RECOMMENDATIONS 14
6.0 REFERENCES 15
APPENDIX A DETAILED ARSENIC SPECIATION RESULTS
APPENDIX B DETAILED RESULTS FROM STUDY 1
APPENDIX C DETAILED RESULTS FROM STUDY 2
VBI70 Arsenic RBA Final.doc
ill
-------
LIST OF TABLES
TABLE TITLE
2-1 Study Design
2-2 Arsenic Concentrations in Test Materials
LIST OF FIGURES
FIGURE TITLE
2-1 Arsenic Concentrations in Test Materials
2-2 Body Weight Gain
2-3 Performance Evaluation Samples
2-4 Blind Duplicate Samples
2-5 Inter-Laboratory Comparison
3-1 Conceptual Model for Arsenic Toxicokinetics
4-1 Urinary Excretion of Arsenic From Sodium Arsenate (Study 1)
4-2 Urinary Excretion of Arsenic From Test Soil 1 (Study 1)
4-3 Urinary Excretion of Arsenic From Test Soil 2 (Study 1)
4-4 Urinary Excretion of Arsenic From Test Soil 3 (Study 1)
4-5 Urinary Excretion of Arsenic From Sodium Arsenate (Study 2)
4-6 Urinary Excretion of Arsenic From Test Soil 4 (Study 2)
4-7 Urinary Excretion of Arsenic From Test Soil 5 (Study 2)
4-8 Urinary Excretion of Arsenic From Test Soil 6 (Study 2)
4-9 Dose Confirmation Sample Results
4-10 Combined Data for Sodium Arsenate
4-11 Relation Between Urinary and Fecal Excretion
4-12 In Vivo RBA vs In Vitro BA
VBI70 Arsenic RBA Final.doc
iv
-------
RELATIVE BIOAVAILABILITY OF ARSENIC IN VBI70 SITE SOILS
1.0 INTRODUCTION
Accurate assessment of the health risks resulting from oral exposure to any chemical frequently
requires knowledge of the amount of the chemical absorbed from the gastrointestinal tract into
the body. This information on absorption may be described either in absolute or relative terms:
Absolute Bioavailability (ABA) is the ratio of the amount of chemical absorbed
compared to the amount of chemical ingested:
Absorbed Dose
ABA =
Ingested Dose
This ratio is also referred to as the oral absorption fraction (AF0).
Relative Bioavailability (RBA) is the ratio of the absolute bioavailability of some test
material compared to the absolute bioavailability of some appropriate reference
material, usually the chemical dissolved in water or some fully soluble form that
completely dissolves when ingested:
ABA (test material)
RBA V 7
ABA (reference material)
For example, if 100 ug of arsenic dissolved in drinking water were ingested and a total of 90 ug
entered the body, the ABA would be 0.90 (90%). Likewise, if 100 ug of arsenic contained in
soil were ingested and 30 ug entered the body, the ABA for soil would be 0.30 (30%). If the
arsenic dissolved in water were used as the reference substance for describing the relative
amount of arsenic absorbed from soil, the RBA would be 0.30/0.90 = 0.33 (33%).
Using Bioavailability Data to Improve Risk Calculations for Arsenic
When reliable data are available on the bioavailability of arsenic in soil, dust or other soil-like
waste material at a site, this information can be used to improve the accuracy of exposure and
risk calculations at that site. Because the reference dose (RfD) and the slope factor (SF) for
arsenic are both expressed in terms of dose of soluble arsenic ingested in water, the adjustment
is most conveniently achieved by using the bioavailability data to modify the toxicity values to
account for differences in absorption between arsenic ingested in water and the absorption of
arsenic from site media. This is done as follows:
A BA {water)
RfDiadjusted) = RfD(IRIS) ¦ V 7
ABA(site medium)
VBI70 Arsenic RBA Final.doc
1
-------
ABAisite medium)
SF{adjusted) = SF(IRIS) ¦ ——
ABA(water)
If an RBA value is available that is based on a reference form of arsenic that is as well
absorbed as arsenic in water, then the adjustments may be made as follows:
RfD (IRIS)
RfD(adjusted) =
SF (adjusted) = SF (IRIS) ¦ RBA
Alternatively, it is also acceptable to adjust the dose (rather than the toxicity factors) as follows:
Dose(adjusted) = Dose(default) ¦ RBA
This adjustment in dose is mathematically equivalent to adjusting the toxicity factors as
described above.
Purpose of this Study
Investigations performed at the Vasquez Boulevard and 1-70 (VBI70) Superfund site in Denver,
Colorado, have revealed that some residential properties have yard soil that is contaminated
with elevated levels of arsenic. This study was performed in order to obtain site-specific data
on the relative bioavailability of arsenic in yard soils in order to help improve the accuracy of
risk calculations for residents who may be exposed to arsenic in soil.
VBI70 Arsenic RBA Final.doc
2
-------
2.0 STUDY DESIGN
This investigation of arsenic absorption and excretion was performed in two sequential studies.
The basic design for each of these two studies is presented in Table 2-1. As shown, each study
investigated arsenic absorption from sodium arsenate (the reference material) and from three site-
specific soils, each administered to groups of animals at two different dose levels for 12 days. All
doses were administered orally.
2.1 Test Materials
Sample Selection
Test Materials 1 to 5 were samples of residential yard soil that were collected during Phase 3 or
the risk-based sampling activities at the VBI70 site. Samples were selected to cover a range of
arsenic concentrations in soil, and were also selected to provide reasonable spatial
representativeness across the site, including samples from the Swansea/Elyria, Cole and
Clayton neighborhoods. Soils with arsenic concentrations less than 200-250 ppm were not
included because the mass of soil required for swine dosing was not available. Test Material 6
was prepared by mixing clean site soil (As <10 ppm) with sufficient PAX (an arsenical
herbicide that is considered to be a potential source material) to yield a concentration of
approximately 516 ppm arsenic.
Sample Preparation
In all cases, each Test Material was prepared by combining all soil samples that had been
collected from the selected property. For example, for properties that had been sampled during
the risk-based sampling program (Test Materials 1 and 2), over 100 subsamples of soil were
combined. For properties selected from the Phase 3 program (Test Materials 3-5), three
samples (each a composite of 10 subsamples) were combined.
All sub-samples from a property were composited using a stainless steel bowl and mixing
spoon. The composites were then air dried, homogenized, and sieved to < 250 //m. Soil for
Test Material 6 was also prepared by drying and sieving prior to the addition of the PAX.
Arsenic Concentration
After compositing, drying, mixing, and sieving, the concentration of arsenic was measured in
each Test Material by several techniques. An initial estimate was derived by x-ray
fluorescence (XRF), and these initial values were used to calculate the dose of each soil to
administer to the test animals. Subsequently, additional aliquots of each Test Material were re-
analyzed by XRF and also by inductively coupled plasma (ICP) spectroscopy and by neutron
activation analysis (NAA). The results from these analyses are presented in Table 2-2 and are
shown graphically in Figure 2-1. As seen, although there is reasonable agreement among the
different measurements, the initial set of XRF values (XRF-1) tended to be somewhat higher
than the second set of XRF values (XRF-2) and the ICP and NAA values. For this reason, all
VBI70 Arsenic RBA Final.doc
3
-------
final calculations of administered dose were based on the mean of the XRF-2, ICP and NAA
values.
Sample Speciation
An aliquot of each test material was analyzed by electron microprobe in order to identify the
different mineral forms of arsenic that were present in the sample and to estimate
approximately how much of the total arsenic was present in each form. The detailed results are
presented in Appendix A, and the results are summarized below:
Arsenic Speciation Data
Test
Material
Number of
Grains
Counted
Relative Arsenic Mass
Particle Size (um)
AS2O3
PbAsO
All Other
<10
10-50
>50
TM1
262
54.3%
31.9%
13.8%
88.5%
10.7%
0.4%
TM2
128
22.1%
70.0%
7.9%
78.1%
19.5%
0.0%
TM3
104
81.0%
5.6%
13.4%
72.1%
26.9%
0.0%
TM4
144
87.1%
10.0%
3.0%
73.6%
24.3%
1.4%
TM5
134
96.8%
--
3.2%
72.4%
27.6%
0.0%
TM6
133
80.1%
18.2%
1.7%
86.5%
12.0%
0.0%
Inspection of these data reveals the following main observations:
• Arsenic in most site soils consists mainly as arsenic trioxide (AS2O3) and lead arsenic
oxide (PbAsO).
• Most arsenic (72% to 88%) occurs in particles that are smaller than 10 um in diameter.
• Essentially all arsenic-bearing grains are "liberated" (i.e., they are not contained within
any other matrix).
It is important to note that these quantitative estimates of particle frequency and relative arsenic
mass are based on examination of a relatively small number of arsenic-bearing particles (N =
104 to 262) in each sample. Consequently, the quantitative values reported should not be
considered to be highly precise, and apparent differences between samples may be due to
random variation in the analysis rather than authentic differences in composition.
VBI70 Arsenic RBA Final.doc
4
-------
2.2 Experimental Animals
Young swine were selected for use in these studies because they are considered to be a good
physiological model for gastrointestinal absorption in children (Weis and LaVelle 1991). The
animals were Pig Improvement Corporation (PIC) genetically defined Line 26, and were
purchased from Chinn Farms, Clarence, MO. Animals used in study 1 were intact males, while
animals used for study 2 were castrated males.
The animals were housed in individual stainless steel cages. All animals were held for several
days prior to beginning exposure to test materials to allow them to adapt to their new
environment and to ensure that all of the animals were healthy. In order to help minimize
weight variations between animals and groups, three animals most different in body weight on
day -1 (either heavier or lighter) were also excluded. The remaining animals were assigned to
dose groups at random. When exposure began (day zero), the animals were about 5-6 weeks
old and weighed an average of about 8.9 kg (Study 1) or 7.0 kg (Study 2). Animals were
weighed every three days during the course of each study. On average, animals gained about
0.4 to 0.5 kg/day, and the rate of weight gain was comparable in all groups. These body weight
data are summarized in Figure 2-2.
2.3 Diet
Each day every animal was given an amount of standard swine chow (University Feed Mill S II
(2) starter ration without added antibiotics) equal to 5% of the mean body weight of all animals
on study. Feed was administered in two equal portions (2.5% of the mean body weight) at 11:00
AM and 5:00 PM daily. Drinking water was provided ad libitum via self-activated watering
nozzles within each cage.
Periodic analysis of four water and two feed samples during this program yielded the following:
Water (ug/L)
Diet (ug/g)
2
<1
0.23
<1
0.15
<1
Based on these data, estimated intake of arsenic in unexposed animals is less than 0.1 ug/kg-day
via water and about 10 ug/kg-day via the diet.
2.4 Dosing
Animals were exposed to sodium arsenate (abbreviated in this report as "NaAs") or test material
(site soil) for 12 days, with the dose for each day being administered in two equal portions
given at 9:00 AM and 3:00 PM (two hours before feeding). Dose material was placed in the
center of a small portion (about 5 grams) of moistened feed (this is referred to as a doughball"),
and this was administered to the animals by hand.
VBI70 Arsenic RBA Final.doc
5
-------
The dose levels administered were based on the arsenic content of the test material, with target
doses of 50 and 125 ug/kg-day for NaAs and each test material. As noted previously (see
Section 2.1), original dose calculations were made using the initial XRF analysis of arsenic
concentrations in the test materials (see XRF-1 values in Table 2-2). Actual administered
arsenic doses were re-calculated using the mean of subsequent analyses of the samples by XRF,
ICP and NAA (see Table 2-2) and measured body weights. These actual administered doses
are presented in Appendix B (Study 1) and Appendix C (Study 2).
2.5 Collection and Preparation of Samples
Urine
Samples of urine were collected from each animal for three consecutive 48-hour periods, on
days 6/7, 8/9 and 10/11. Collection began at 9AM and ended 48 hours later. The urine was
collected in a stainless steel pan placed beneath each cage, which drained into a plastic storage
bottle. Each collection pan was fitted with a nylon screen to minimize contamination with
feces, spilled food or other debris. Plastic diverters were used to minimize urine dilution with
drinking water spilled by the animals from the watering nozzle into the collection pan, although
this was not always effective in preventing dilution of the urine with water. Due to the length
of the collection period, collection containers were emptied at least twice daily into a separate
holding container. This ensured that there was no loss of sample due to overflow.
At the end of each collection period, the urine volume was measured and 60-mL portions were
removed for analysis. A separate 250-mL aliquot was retained as an archive sample. Each
sample was acidified by the addition of concentrated nitric acid. The samples were stored
refrigerated until arsenic analysis.
Feces
Feces were collected by placing a fine-mesh nylon screen beneath each cage. Samples were
transferred from the screen into a storage container twice per day, and the final sample
(collected over 48 hours) was weighed. Aliquots of 20-25 grams of feces were weighed and
freeze dried.
2.6 Arsenic Analysis
Urine
Urine samples were arranged in a random sequence and submitted to the laboratory for analysis
in a blind fashion.
Details of urine sample preparation and analysis are provided in the study project plan (EPA
1999). In brief, 25 mL samples of urine were digested by refluxing and then heating to dryness
in the presence of magnesium nitrate and concentrated nitric acid. Following magnesium
nitrate digestion, samples were transferred to a muffle furnace and ashed at 500°C. The
digested and ashed residue was dissolved in hydrochloric acid and analyzed by the hydride
VBI70 Arsenic RBA Final.doc
6
-------
generation technique using a Perkin-Elmer 3100 atomic absorption spectrometer. Preliminary
tests of this method established that each of the different forms of arsenic which may occur in
urine, including trivalent inorganic arsenic (As+3), pentavalent inorganic arsenic (As+5),
mono-methyl arsenic (MMA) and di-methyl arsenic (DMA) are all recovered with high
efficiency.
A number of quality assurance steps were taken during this project to evaluate the accuracy of the
analytical procedures. Steps performed by the analytical laboratory included:
Spike Recovery
Randomly selected samples were spiked with known amounts of arsenic (usually 5-10 ug,
as sodium arsenate) and the recovery of the added arsenic was measured. Recovery for
individual samples typically ranged from 87% to 115%, with an average across all
analyses of 103 ± 5.2 % (N = 41).
Duplicate Analysis
Random samples were selected for duplicate analysis by the laboratory analyst. Duplicate
results typically had a relative percent difference (RPD) of 1-10%, with an average of 8.7
% (N = 81).
Standards
Samples of two different urine standards were run with each set of test samples. One
standard was a urine standard obtained from NIST (sample number 2670 Elevated) with a
nominal arsenic concentration of 480 ±100 ug/L. Results for this standard ranged from
530 to 560 ug/L, with a mean across all samples of 544.3 ± 9.6 ug/L (N = 7). The second
standard was an aqueous solution obtained from ERA (sample 9978) with a nominal
concentration of 92.9 ug/L. Results for this standard ranged from 92 to 102 ug/L, with a
mean across all samples of 96.2 ±1.7 ug/L (N =90).
Blanks
Blank samples run along with each batch of samples never yielded a measurable level of
arsenic, with all values being reported as less than 0.05 ug of arsenic.
In addition to these laboratory-sponsored QA procedures, an additional series of QA samples were
submitted to the laboratory in a blind fashion. This included a number of Performance Evaluation
(PE) samples (urines of known arsenic concentration) as well as a number of blind duplicates.
The results for the PE samples are shown in Figure 2-3. As seen, the PE samples included several
different concentrations each of several different types of arsenic (As+3, As+5, MMA and DMA,
both alone and in a mixture). In nearly all cases, there was good recovery of the arsenic in both
the first and the second study.
VBI70 Arsenic RBA Final.doc
7
-------
The results for blind duplicates are shown in Figure 2-4. As seen, there was good agreement
between results for the duplicate pairs in both the first and second study.
As a final check, a series of samples were submitted to a second laboratory for inter-laboratory
comparison of results. This included investigative samples (urines collected from study animals)
as well as several PE samples. The results are shown in Figure 2-5. As seen, there is generally
good agreement between the two laboratories.
Based on the results of all of the quality assurance samples and steps described above, it is
concluded that the analytical results for samples of urine are of high quality and are suitable for
derivation of reliable estimates of arsenic absorption from test materials.
Feces
After drying, 1.0 gram of fecal material was removed and digested with 10 mL of magnesium
nitrate and nitric acid using the same approach as described above for urine. Following
digestion, all sample preparation and analytical steps are the same as for urine.
VBI70 Arsenic RBA Final.doc
8
-------
3.0 DATA ANALYSIS
Figure 3-1 shows a conceptual model for the toxicokinetic fate of ingested arsenic. Key points
of this model are as follows:
• In most animals (including humans), absorbed arsenic is excreted mainly in the
urine over the course of several days. Thus, the urinary excretion fraction (UEF),
defined as the amount excreted in the urine divided by the amount given, is usually
a reasonable approximation of the oral absorption fraction or ABA. However, this
ratio will underestimate total absorption, because some absorbed arsenic is excreted
in the feces via the bile, and some absorbed arsenic enters tissue compartments (e.g.,
skin, hair, etc.) from which it is cleared very slowly or not at all. Thus the urinary
excretion fraction should not be equated with the absolute absorption fraction.
• The relative bioavailability (RBA) of two orally administered materials (e.g., test
material and reference material) can be calculated from the ratio of the urinary
excretion fraction of the two materials. This calculation is independent of the extent
of tissue binding and of biliary excretion:
AF0 {test) D ¦ AF0 {test) ¦ Ku UEF {test)
RBA(test vs ref) = = =
^ J) AFa{ref) D ¦ AFa {ref) ¦ Ku UEF {ref)
Based on the conceptual model above, raw data from this study were reduced and analyzed as
follows:
• The amount of arsenic excreted in urine by each animal over each collection period
was calculated by multiplying the urine volume by the urine concentration:
Excreted (ug/48hr) = Cone (ug/L) • Volume (L/48hr)
• For each test material, the amount of arsenic excreted by each animal was plotted as
a function of the amount administered (ug/48 hours), and the best fit straight line
(calculated by linear regression) through the data (ug excreted per ug administered)
was used as the best estimate of the urinary excretion fraction (UEF).
• The relative bioavailability of arsenic in test material was calculated as:
RBA = UEF(test) / UEF(NaAs)
where sodium arsenate (NaAs) is used as the frame of reference.
• As noted above, each RBA value is calculated as the ratio of two slopes (UEFs),
each of which is estimated by linear regression through a set of data points.
Because of the variability in the data, there is uncertainty in the estimated slope
VBI70 Arsenic RBA Final.doc
9
-------
(UEF) for each material. This uncertainty in the slope is described by the standard
error of the mean (SEM) for the slope parameter. Given the best estimate and the
SEM for each slope, the uncertainty in the ratio may be estimated using Monte
Carlo simulation. The probability density function describing the confidence
around each slope (UEF) term was assumed to be characterized by a t-distribution
with n-2 degrees of freedom :
UEF {measured) - UEF(true)
SEM tn~2
For convenience, this PDF is abbreviated T(slope, sem, n), where slope = best
estimate of the slope derived by linear regression, sem = standard deviation in the
best estimate of the slope, and n = number of data points upon which the regression
analysis was performed. Thus, the confidence distribution around each ratio was
simulated as:
T( slope, sem, ri)t
PDF(RBA) ' Jt
T(slope, sem, n)ref
Using this equation, a Monte Carlo simulation was run for each RBA calculation.
The 5th and 95th percentile values from the simulated distribution of RBA values
were then taken to be the 90% confidence interval for the RBA.
VBI70 Arsenic RBA Final.doc
10
-------
4.0 RESULTS
The doses of arsenic administered in this study are below a level that is expected to cause
toxicological responses in swine, and no clinical signs of arsenic-induced toxicity were noted in
any of the animals used in either Study 1 or Study 2.
4.1 Urinary Excretion Fractions
Detailed results from Study 1 and Study 2 are presented in Appendices B and C, respectively. The
results for urinary excretion of arsenic are summarized in Figures 4-1 to 4-8. Although there is
variability in the data, most dose-response curves are approximately linear, with the slope of the
best-fit straight line being equal to the best estimate of the urinary excretion fraction (UEF). This
finding is consistent with results from both animals and humans, which suggest that there is no
threshold for arsenic absorption or excretion up to doses of at least 5,000 ug/day (EPA 1995).
An exception to this pattern is observed for sodium arsenate in Study 1. As seen in Figure 4-1, the
dose-response curves on days 6-7 and days 8-9 are not well-described by a linear model. The
basis of this unexpected result appears to be the values derived for the low dose group. Indeed, the
amount of arsenic recovered in the urine of low-dose group animals on days 6-7 and 8-9 was more
than the nominal dose administered. Therefore, samples of the doughballs administered for the
time interval in question were analyzed in order to determine if the actual dose delivered to the
animals was that which was intended. The results are shown in Figure 4-9. As seen, it is clear that
an error occurred in the preparation of doughballs that were administered to Dose Group 2 on
study days 6-8. This in turn explains why the amount excreted in urine of animals from this group
was much higher than expected on days 6-7, and was somewhat higher than expected on days 8-9.
For this reason, the data points for animals in Dose Group 2 (the low dose of sodium arsenate) in
Study 1 on days 6-7 and 8-9 are judged to be erroneous and were excluded from the analysis.
Figure 4-10 shows the data set for sodium arsenate from Study 1 and Study 2 combined after
exclusion of these data points, along with the best fit regression line through the data.
The following table summarizes the best fit slopes (urinary excretion fractions) for sodium
arsenate and each of the test materials.
Summary of UEF Values
Test Material
Slope (UEF) ± SEM
NaAs
0.695 ± 0.038
TM1
0.243 ± 0.036
TM2
0.310 ± 0.023
TM3
0.254 ± 0.017
TM4
0.145 ± 0.015
TM5
0.122 ± 0.010
TM6
0.159 ± 0.016
VBI70 Arsenic RBA Final.doc
11
-------
4.2 Calculation of Relative Bioavailability
As discussed above, the relative bioavailability of arsenic in a specific test material is
calculated as follows:
RBA(test vs NaAs) = UEF(test) / UEF(NaAs,oral)
The results are summarized below:
Test Material
Relative I
•ioavailability
Best Estimate
90% Confidence Interval
TM1
0.35
0.26 - 0.45
TM2
0.45
0.38-0.52
TM3
0.36
0.31-0.42
TM4
0.21
0.17-0.25
TM5
0.18
0.15-0.21
TM6
0.23
0.19-0.28
4.3 Fecal Excretion and Mass Balance
As shown in Figure 3-1, the amount of arsenic excreted in the feces is the sum of that which is
ingested but never absorbed, and that which is absorbed and then secreted in bile back into the
intestines. Assuming that biliary excretion of absorbed arsenic is a relatively minor metabolic
pathway, then the amount of arsenic excreted in the feces is expected to be high when the
urinary excretion fraction (and hence the RBA) is low.
Figure 4-11 plots the fecal excretion fraction (defined as the mass of arsenic excreted in feces
in 48 hours divided by the oral dose of arsenic administered in 48 hours) as a function of the
urinary excretion fraction. As seen, there is a clear negative trend, with low urinary excretion
being associated with high fecal excretion.
The sum of the two excretion fractions is equal to the total fraction of the administered dose
recovered in urine plus feces. These data are summarized below.
Mass Balance for Arsenic
Test Material
UEF
FEF
Total
NaAs
0.695
0.040
0.74
TM1
0.243
0.417
0.66
TM2
0.310
0.408
0.72
TM3
0.254
0.272
0.53
TM4
0.145
0.476
0.62
TM5
0.122
0.646
0.77
TM6
0.159
0.689
0.85
VBI70 Arsenic RBA Final.doc
12
-------
As seen, the total fraction of the administered arsenic that was recovered in urine and feces
averaged about 70% (range = 53%-85%). This recovery is consistent with most other studies
of arsenic excretion in animals (USEPA 1995).
4.4 In Vitro Bioaccessability
Recently, an alternative approach for estimating the solubility (and hence the potential toxicity)
of arsenic in soils and other solid material has been developed. The details of the approach are
described in the project plan for this study (USEPA 1999). In brief, samples of soil are placed
in a test fluid designed to be similar to gastric fluid, and the fraction of the total amount of
arsenic in the sample which dissolves into the fluid under a specified set of conditions
(temperature, time, pH) is measured. This fraction of the total that is solubilized is referred to
as the in vitro bioaccessability (IVBA). IVBA results for the six test materials in this study are
summarized below:
Test Material
IVBA (%)
TM1
41.8
TM2
33.2
TM3
40.3
TM4
22.0
TM5
19.3
TM5 (dup)
18.2
TM6
17.6
TM6 (dup)
19.6
Because of the many differences between the in vitro test system and the gastrointestinal tract
of a living organism (swine, human), it is not expected that the IVBA for a sample should be
equal to the ABA or the RBA for that sample. However, if solubility is a key determinant of
ABA and RBA, then it is expected that there should be a correlation between IVBA and RBA.
Figure 4-12 plots the measured IVBA values as a function of the measured RBA values. As
seen, there is a moderately good correlation between RBA and IVBA (R2 = 0.645), with a
slope of 0.8 and an intercept near zero. This indicates that, at this site, an in vitro measurement
of bioaccessability is a moderately good predictor of in vivo gastrointestinal absorption.
VBI70 Arsenic RBA Final.doc
13
-------
5.0 DISCUSSION AND RECOMMENDATIONS
The RBA results for site soils collected from the VBI70 study area range from about 0.18 to 0.45,
with a mean of about 0.31. These values are all less than the default value of 0.8 recommended by
USEPA Region VIII, supporting the conclusion that arsenic in VBI70 site soils is not as well
absorbed as soluble arsenic. The detailed chemical mechanism accounting for this reduced
bioavailability of arsenic in site soils is not known, but almost certainly is related to the chemical
form of arsenic in the soils.
As shown in Appendix A and discussed in Section 2.1, all of the site soils evaluated in this
study are characterized by a mixture of arsenic trioxide and lead arsenic oxide particles, with
most of the particles being less than 10 um in diameter. Based on this general similarity in
composition and particle size distribution, it is concluded that the apparent variations in RBA
between different site samples is likely to be due mainly to random variations in bioassay
results, and that the best estimate of an RBA value for the site should be based on the combined
information from all five site soils (TM1 to TM5). Since TM6 is not an actual site sample, data
from TM6 were not included in the summary statistics. Because of the inherent variability and
uncertainty in the data, the 95% UCL of the mean is recommended as the most appropriate
statistic for use in assessing human health risk from arsenic in soil. Summary statistics for the
combined data are presented below:
Estimated Site-Wide I
tBA for Arsenic in Soil
Statistic
Value
Mean
0.31
Stdev
0.11
95% UCLa
0.42
a Assumes a normal distribution
VBI70 Arsenic RBA Final.doc
14
-------
6.0 REFERENCES
USEPA. 1999. Quality Assurance Project Plan for Vasquez Blvd-170. Bioavailability of Arsenic
in Site Soils Using Juvenile Swine as an Animal Model. Report prepared by IS SI Consulting
Group for USEPA Region VIII. September, 1999.
Weis, C.P. and LaVelle, J.M. 1991. Characteristics to consider when choosing an animal
model for the study of lead bioavailability. In: The Proceedings of the International
Symposium on the Bioavailability and Dietary Uptake of Lead. Science and Technology
Letters 3:113-119.
VBI70 Arsenic RBA Final.doc
15
-------
TABLE 2-1 STUDY DESIGN
Study 1
Group
Number of
Material
Dose
Target Dose
Animals
Administered
Route
(ug As/kg-day)
1
3
Control
Oral
0
2
4
NaAs
Oral
50
3
4
NaAs
Oral
125
4
4
Test material 1
Oral
50
5
4
Test material 1
Oral
125
6
4
Test material 2
Oral
50
7
4
Test material 2
Oral
125
8
4
Test material 3
Oral
50
9
4
Test material 3
Oral
125
Study 2
Group
Number of
Material
Dose
Target Dose
Animals
Administered
Route
(ug As/kg-day)
1
3
Control
Oral
0
2
4
NaAs
Oral
50
3
4
NaAs
Oral
125
4
4
Test material 4
Oral
50
5
4
Test material 4
Oral
125
6
4
Test material 5
Oral
50
7
4
Test material 5
Oral
125
8
4
Test material 6
Oral
50
9
4
Test material 6
Oral
125
-------
TABLE 2-2 ARSENIC CONCENTRATIONS IN TEST MATERIALS
Test
Material
Description
XRF-1
XRF-2
ICP
NAA
Mean3
1
Soil composite from a residential
property in eastern Swansea/Elyria
422
318
290
328
312
2
Soil composite from a residential
property in western Swansea/Elyria
1450
1041
856
1053
983
3
Soil composite from a residential
property in eastern Cole
710
419
343
408
390
4
Soil composite from a residential
property in western Cole
1087
821
756
862
813
5
Soil composite from a residential
property in Clayton
448
352
329
423
368
6
PAX added to a clean site soil from a
property in Swansea/Elyria
796
503
459
586
516
a Mean excludes XRF-1
Cone in Test materials.xls
-------
FIGURE 2-1 ARSENIC CONCENTRATIONS IN TEST MATERIALS
1600
1400 -
E 1200
Q.
c 1000
<
o
c
o
15
800 -
o
O
600 -
400 -
200 -
•
M
•
A
X
•
A
•
X
•
n
1
A
H
TM-1
TM-2
TM-3
TM-4
TM-5
TM-6
»XRF-1
IXRF-2
AICP
XNAA
Cone in Test materials.xls
-------
FIGURE 2-2 BODY WEIGHT GAIN
—~—Grp 1
¦—Grp 2
Grp 3
Grp 4
¦ ¦ -X- ¦ ¦ Grp 5
Grp 6
—I—Grp 7 -
Grp 8
Grp 9
—~—Grp 1
¦—Grp 2
Grp 3
Grp 4
¦ ¦ -X- ¦ ¦ Grp 5
Grp 6
—I—Grp 7 -
Grp 8
Grp 9
Body weight gain.xls
-------
FIGURE 2-3 PERFORMANCE EVALUATION SAMPLES
120
¦o
CD
£
CD
CO
¦Q
o
80
40
40
80
Nominal (ug/L)
120
O Control
~ As(+3)
¦ As(+5)
AMMA
A DMA
X Mixture
¦a
CD
£
CD
C/5
¦Q
o
120
80
40
PE Samples: Study 2
A*.-
0
*
~ ~ \
¦ B\
*
*
*
*
*
X
40
80
Nominal (ug/L)
120
R:\BioavailabilityWBI70\PE Sample Plots.xlslntralab PE
-------
FIGURE 2-4 BLIND DUPLICATE SAMPLES
1200 -
Blind Duplicates: Study 1
800 -
400
400 800
Original Value (ug/L)
1200
600 n
500 -
O) 400
CD
> 300
CD
-I—»
CO
O
1i 200 ^
Q
100 J
Blind Duplicates: Study 2
*
*
*
*
*
*
*
*
*
*
.X"
*
*
*
*
*
*
...f
100 200 300 400
Original Value (ug/L)
500
600
R:\Swine Bioavailability\PE Sample Plots.xlslntralab Dups
-------
FIGURE 2-5. INTER-LABORATORY COMPARISON
10000 -|
a
O)
.Q
03
_l
TD
C
8 100
w
E
o
c/)
Study 1
A
A
A
^A 4-''
A * ,-''A
A '
a
"5
C/)
CD
A Investigative Samples
q:
~ PE Samples
1 -
*
^ *
100
10000
Results from Primary Lab (ug/L)
10000 -i
O)
-Q
CD
1
TD
C
Study 2
/
A
A'
A.-'
A
V "
w 100
E
o
C/)
H—'
aAA
a"
3
C/)
CD
q:
A Investigative Samples
~ PE Samples
1 -
,,
100
10000
Results from Primary Lab (ug/L)
R:\Swine Bioavailability\lnter-Lab Figures.xIsFigure 2-5
-------
FIGURE 3-1 CONCEPTUAL MODEL FOR ARSENIC TOXICOKINETICS
INGESTED DOSE (D)
AFr
1-AFn
Absorbed
Blood
Non-Absorbed
—~
Ku ^
-> Tissue (T)
-+ Bile (TO
-+¦ Feces (F)
where:
AF0 = Oral Absorption Fraction
= Fraction of absorbed arsenic which is retained in tissues
Ku = Fraction of absorbed arsenic which is excreted in urine
Kb = Fraction of absorbed arsenic which is excreted in the bile
BASIC EQUATIONS:
Amount in Urine
U oral = D • AF 0 * Ku
Uiv = D •Ky
Urinary Excretion Fraction (UEF)
U oral
UEF oral ~
Doral
- AFo• Ku
UEFiv = —= Ku
Dj
IV
Bioavailability
ABA = UEporal = = AF
UEFiv Ku
UEForal AF0(x) • Ku _ AFp(*)
(XVSy) ~ UEF y oral ~ AF0(y)'Ku ~ AF0(y)
-------
FIGURE 4-1 URINARY EXCRETION OF ARSENIC FROM SODIUM ARSENATE
(Study 1)
4000
0.0 1000.0 2000.0 3000.0
Dose of Arsenic (ug/48 hrs)
4000.0
O)
3
0)
-------
FIGURE 4-2 URINARY EXCRETION OF ARSENIC FROM TEST SOIL 1
(Study 1)
3000
O)
3
2000 --
=>
c
c
o
o
X
LU
c
CD
-------
FIGURE 4-3 URINARY EXCRETION OF ARSENIC FROM TEST SOIL 2
(Study 1)
Dose of Arsenic (ug/48 hrs)
3000
O)
3
£ 2000 --
Z)
c
T3
0)
O
X
LD
c
a)
(/)
1000 --
Days 8-9
y = 0.3665x + 103.84
+
+
+
+
500 1000 1500 2000 2500
Dose of Arsenic (ug/48 hrs)
3000
VBIurinemast revised.xls
-------
FIGURE 4-4 URINARY EXCRETION OF ARSENIC FROM TEST SOIL 3
(Study 1)
O)
3
3000
Days 6-7
=>
c
c
o
2000 --
y = 0.2139x + 119.18
1000 --
c
CD
"O
CD
O
X
LU
c
CD
(f)
1000 --
0.0 500.0 1000.0 1500.0 2000.0 2500.0 3000.0
Dose of Arsenic (ug/48 hrs)
O)
3
CD
C
c
o
o
X
LU
c
CD
C/)
3000
2000 --
1000 --
0.0 500.0 1000.0 1500.0 2000.0 2500.0 3000.0
Dose of Arsenic (ug/48 hrs)
O)
3
CD
_C
3
"O
CD
3000
2000 --
~cd 1000 --
o
X
LU
c
CD
(f)
Days 6-11
y = 0.2536x + 129.36
0.0 500.0 1000.0 1500.0 2000.0 2500.0 3000.0
Dose of Arsenic (ug/48 hrs)
VB1 urinemast.xls
-------
FIGURE 4-5 URINARY EXCRETION OF ARSENIC FROM SODIUM ARSENATE
(Study 2)
3000
00
=5
(D
C
=5
c
c
o
Days 6-7
2000 --
y = 0.6247x + 110.69
o
x
LU
O
'c
CD
CO
1000 --
1000
2000
3000
Dose of Arsenic (ug/48 hrs)
3000
00
Days 10-11
2000 --
y = 0.548x + 124.05
"O
(D
1000 --
(D
CO
1000 2000
Dose of Arsenic (ug/48 hrs)
3000
V 3000
00
=5
(D
C
3
c
"O
(D
2000 --
o
X
LU
o
'c
(D
CO
1000 --
Days 8-9
0.647x + 88.816
500 1000 1500 2000 2500
Dose of Arsenic (ug/48 hrs)
3000 3500
y 3000
00
2000 --
"O
CD
1000 --
CD
-------
FIGURE 4-6 URINARY EXCRETION OF ARSENIC FROM TEST SOIL 4
(Study 2)
3000
00
Days 6-7
C 2000 --
y = 0.1434x + 84.613
o
-4—1
(D
O
X
LU
(D
CO
1000 --
1000
2000
3000
Dose of Arsenic (ug/48 hrs)
3000
00
=3
| 2000 +
=5
c
"O
0)
O
X
LU
O
'c
(D
CO
1000 --
Days 8-9
y = 0.1173x + 108.24
500
1000
1500
2000
2500
3000
Dose of Arsenic (ug/48 hrs)
3000
00
Days 10-11
2000 --
T3
CD
y = 0.1698x + 103.9
1000 --
1000 2000
Dose of Arsenic (ug/48 hrs)
3000
3000
00
2000 --
T3
(U
1000 --
Days 6-11
y = 0.1454x + 97.361
1000 2000
Dose of Arsenic (ug/48 hrs)
3000
VB2urinemast revised.xls
-------
FIGURE 4-7 URINARY EXCRETION OF ARSENIC FROM TEST SOIL 5
(Study 2)
3000
00
Days 6-7
c 2000 --
y = 0.1007x + 130.43
o
-4—1
(D
O
X
LU
(D
CO
1000 --
I I
1000 2000
Dose of Arsenic (ug/48 hrs)
3000
3000
00
=5
2000 --
z>
c
"O
(D
O
X
LU
O
'c
(D
CO
1000 --
Days 8-9
y = 0.1211x + 97.277
+
-h
+
500 1000 1500 2000
Dose of Arsenic (ug/48 hrs)
2500
3000
3000
00
2000 --
y = 0.1415x + 96.113
T3
(U
1000 --
Days 10-11
1 1
1000 2000
Dose of Arsenic (ug/48 hrs)
3000
3000
00
2000 --
"D
(D
1000 --
(/)
<
Days 6-11
y = 0.1222x + 107.26
1=
+
1000 2000
Dose of Arsenic (ug/48 hrs)
3000
VB2urinemast revised.xls
-------
FIGURE 4-8 URINARY EXCRETION OF ARSENIC FROM TEST SOIL 6
(Study 2)
3000
00
I 2000 -- y = 0.1112x + 96.953
o
-4—1
(D
O
X
LU
(D
CO
1000 --
Days 6-7
1000
2000
3000
Dose of Arsenic (ug/48 hrs)
£ 3000
00
=5
2000 --
z>
c
"O
(D
O
X
LU
O
'c
(D
CO
1000 --
Days 8-9
y = 0.153x + 86.952
I
+
+
+
500 1000 1500 2000
Dose of Arsenic (ug/48 hrs)
2500
3000
00
Days 10-11
2000 --
y = 0.2065x + 81.043
T3
CD
1000 --
1000 2000
Dose of Arsenic (ug/48 hrs)
3000
3000
00
2000 -- y = 0.1592x + 87.002
T3
CD
1000 --
CD
-------
FIGURE 4-9 DOSE CONFIRMATION SAMPLE RESULTS
1200
ro 1000
-Q
o
~C5
O)
3
0
-------
FIGURE 4-10 COMBINED DATA FOR SODIUM ARSENATE
4000
^ 3500
72
5—i
^ 3000
~5ij
g' 2500
¦c
.S 2000
"d
-------
APPENDIX A
DETAILED ARSENIC SPECIATION RESULTS
VBI70 Arsenic RBA Final.doc
1
-------
Test Material 1 - Arsenic
Speciation Summary Statistics
COUNTS
SIZE
Count Freq (%)
LW Freq (%)
Rel. Arsenic Mass (%)
Mineral
Total
Lib
Avg
Min
Max
Total
Liberated
Total
Liberated
Total
Liberated
Clays
5
5
9
2
30
1.9%
1.9%
3.7%
3.7%
0.2%
0.2%
Anglesite
1
1
1
1
1
0.4%
0.4%
0.1%
0.1%
0.0%
0.0%
As203
7
7
10
7
11
2.7%
2.7%
5.4%
5.4%
54.3%
54.3%
Fe Oxide
25
25
12
2
42
9.5%
9.5%
23.6%
23.6%
3.2%
3.2%
Mn Oxide
39
39
7
1
50
14.9%
14.9%
20.8%
20.8%
1.8%
1.8%
PbAsO
52
52
2
1
11
19.8%
19.8%
7.6%
7.6%
31.9%
31.9%
PbMO
1
1
3
3
3
0.4%
0.4%
0.2%
0.2%
0.1%
0.1%
Pb Solder
2
2
21
1
40
0.8%
0.8%
3.3%
3.3%
0.0%
0.0%
Phosphate
128
128
3
1
200
48.9%
48.9%
33.5%
33.5%
8.5%
8.5%
Fe Sulfate
1
1
6
6
6
0.4%
0.4%
0.5%
0.5%
0.1%
0.1%
Ti02
1
1
15
15
15
0.4%
0.4%
1.2%
1.2%
0.0%
0.0%
TOTAL
262
262
5
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
TM 1 Final.xls
-------
Test Material 1 - Speciation and Particle Size Data
Ti02
Fe Sulfate
Phosphate
Pb Solder
PbMO
PbAsO
Mn Oxide
Fe Oxide
As203
Anglesite
Clays
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
100%
80%
60%
O
5
6
250
TM 1_Final.xls: VB-I70 Figures
-------
Test Material 2 - Arsenic
Speciation Summary Statistics
Mineral
COUNTS
SIZE
Count Freq (%)
LW Freq (%)
Rel. As Mass (%)
Total
Lib
Avg
Min
Max
Total
Liberated
Total
Liberated
Total
Liberated
Clays
5
5
7
2
25
3.9%
3.9%
3.0%
3.0%
0.1%
0.1%
As203
7
7
5
1
12
5.5%
5.5%
3.3%
3.3%
22.1%
22.1%
Fe Oxide
24
24
15
3
88
18.8%
18.8%
32.9%
32.9%
3.0%
3.0%
Mn Oxide
5
5
8
3
12
3.9%
3.9%
3.6%
3.6%
0.2%
0.2%
PbAsO
54
54
5
1
80
42.2%
42.2%
25.0%
25.0%
70.0%
70.0%
PbMO
2
2
1
1
1
1.6%
1.6%
0.2%
0.2%
0.1%
0.1%
Phosphate
28
28
10
1
45
21.9%
21.9%
26.1%
26.1%
4.4%
4.4%
Slag
2
2
30
28
32
1.6%
1.6%
5.4%
5.4%
0.0%
0.0%
Fe Sulfate
1
1
5
5
5
0.8%
0.8%
0.5%
0.5%
0.0%
0.0%
TOTAL
128
128
9
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
TM 2 Final.xls
-------
Test Material 2 - Speciation and Particle Size Data
Fe Sulfate
Slag
Phosphate
PbMO
PbAsO
Mn Oxide
Fe Oxide
As203
Clays
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
100%
80%
60%
O
5
6
250
Particle Size (um)
TM 2_Final.xls: VB-170 Figures
-------
Test Material 3 - Arsenic
Speciation Summary Statistics
Mineral
COUNTS
SIZE
Count Freq (%)
LW Freq (%)
Rel. As Mass (%)
Total
Lib
Avg
Min
Max
Total
Liberated
Total
Liberated
Total
Liberated
Clays
7
7
3
1
8
6.7%
6.7%
2.3%
2.3%
0.1%
0.1%
Anglesite
1
1
1
1
1
1.0%
1.0%
0.1%
0.1%
0.0%
0.0%
As203
8
8
6
2
9
7.7%
7.7%
5.2%
5.2%
81.0%
81.0%
Cerussite
2
2
1
1
1
1.9%
1.9%
0.2%
0.2%
0.0%
0.0%
Fe Oxide
28
28
12
1
45
26.9%
26.9%
36.4%
36.4%
7.8%
7.8%
Galena
4
4
1
1
2
3.8%
3.8%
0.5%
0.5%
0.0%
0.0%
Mn Oxide
22
22
17
2
38
21.2%
21.2%
40.6%
40.6%
5.4%
5.4%
PbAsO
6
6
1
1
3
5.8%
5.8%
0.9%
0.9%
5.6%
5.6%
PbCr04
1
1
5
5
5
1.0%
1.0%
0.5%
0.5%
0.0%
0.0%
PbMO
3
3
1
1
1
2.9%
2.9%
0.3%
0.3%
0.3%
0.3%
Pb Solder
1
1
1
1
1
1.0%
1.0%
0.1%
0.1%
0.0%
0.0%
Phosphate
20
20
2
1
8
19.2%
19.2%
3.9%
3.9%
1.5%
1.5%
Slag
1
1
85
85
85
1.0%
1.0%
9.1%
9.1%
0.0%
0.0%
TOTAL
104
104
9
76.0%
76.0%
100.0%
100.0%
100.0%
100.0%
TM 3 Final.xls
-------
Test Material 3 - Speciation and Particle Size Data
Slag
Phosphate
Pb Solder
PbMO
PbCr04
PbAsO
Mn Oxide
Galena
Fe Oxide
Cerassite
As203
Anglesite
Clays
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
100%
80%
60%
O
£ 40%
20%
0%
Panel A: Relative Arsenic Mass
~ Frequency
~ Mass
1 1 1 1 1 1 1 1 r
Panel B: Particle Size Ditribution
<5 5-9 10-19 20-49 50-99 100-149 150-199 200-249 >250
Particle Size (um)
TM 3_Final.xls: VB-170 Figures
-------
Test Material 4 - Arsenic
Speciation Summary Statistics
COUNTS
SIZE
Count Freq (%)
LW Freq (%)
Rel. As Mass (%)
Mineral
Total
Lib
Avg
Min
Max
Total
Liberated
Total
Liberated
Total
Liberated
Clays
9
9
5
1
11
6.3%
6.3%
3.0%
3.0%
0.1%
0.1%
Anglesite
3
3
3
1
8
2.1%
2.1%
0.7%
0.7%
0.0%
0.0%
As203
33
33
7
1
22
22.9%
22.9%
16.2%
16.2%
87.1%
87.1%
AsSbO
3
3
6
2
8
2.1%
2.1%
1.3%
1.3%
0.6%
0.6%
Fe Oxide
40
40
9
1
32
27.8%
27.8%
25.2%
25.2%
1.9%
1.9%
Mn Oxide
14
14
10
2
25
9.7%
9.7%
9.6%
9.6%
0.4%
0.4%
PbAsO
4
4
16
1
60
2.8%
2.8%
4.5%
4.5%
10.0%
10.0%
PbCr04
1
1
8
8
8
0.7%
0.7%
0.6%
0.6%
0.0%
0.0%
PbSi04
2
2
8
3
12
1.4%
1.4%
1.1%
1.1%
0.0%
0.0%
Pb Solder
1
1
2
2
2
0.7%
0.7%
0.1%
0.1%
0.0%
0.0%
Phosphate
20
20
5
1
38
13.9%
13.9%
7.3%
7.3%
1.0%
1.0%
Slag
8
8
50
8
125
5.6%
5.6%
28.3%
28.3%
0.0%
0.0%
Fe Sulfate
6
6
5
2
8
4.2%
4.2%
2.3%
2.3%
0.2%
0.2%
TOTAL
144
144
10
75.7%
75.7%
100.00%
100.00%
100.0%
100.0%
TM 4 Final.xls
-------
Test Material 4 - Speciation and Particle Size Data
Panel A: Relative Arsenic Mass
Fe Sulfate
Slag
Phosphate
Pb Solder
PbSi04
PbCr04
PbAsO
Mn Oxide
Fe Oxide
AsSbO
As203
Anglesite
Clays
~ Frequency
~ Mass
0%
10% 20% 30% 40% 50% 60% 70%
—i 1
80% 90% 100%
Panel B: Particle Size Ditribution
100%
80% --
o
g
&
250
TM 4_Final.xls: VB-170 Figures
-------
Test Material 5 - Arsenic
Speciation Summary Statistics
Mineral
Counts
Size (urn)
Count Freq (%)
LW Freq (%)
Rel. As Mass (%)
Total
Lib
Avg
Min
Max
Total
Liberated
Total
Liberated
Total
Liberated
As203
35
35
7
2
17
26.1%
26.1%
23.1%
23.1%
96.8%
96.8%
Barite
2
2
3
2
3
1.5%
1.5%
0.4%
0.4%
0.0%
0.0%
Brass
3
3
10
2
25
2.2%
2.2%
2.7%
2.7%
0.0%
0.0%
Cerussite
2
2
1
1
1
1.5%
1.5%
0.2%
0.2%
0.0%
0.0%
Fe Oxide
38
38
14
2
45
28.4%
28.4%
48.9%
48.9%
2.8%
2.8%
Mn Oxide
3
3
32
15
42
2.2%
2.2%
8.5%
8.5%
0.3%
0.3%
Paint
1
1
45
45
45
0.7%
0.7%
4.0%
4.0%
0.0%
0.0%
Native Pb
1
1
4
4
4
0.7%
0.7%
0.4%
0.4%
0.0%
0.0%
PbMO
1
1
3
3
3
0.7%
0.7%
0.3%
0.3%
0.1%
0.1%
PbO
1
1
8
8
8
0.7%
0.7%
0.7%
0.7%
0.0%
0.0%
PbSi04
24
24
3
1
8
17.9%
17.9%
5.5%
5.5%
0.0%
0.0%
Pb Solder
16
16
3
1
15
11.9%
11.9%
4.0%
4.0%
0.0%
0.0%
Slag
6
6
2
1
3
4.5%
4.5%
0.8%
0.8%
0.0%
0.0%
Fe Sulfate
1
1
5
5
5
0.7%
0.7%
0.4%
0.4%
0.0%
0.0%
TOTAL
134
134
8.3
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
TM 5 Final.xls
-------
Test Material 5 - Speciation and Particle Size Data
Panel A: Relative Arsenic Mass
Fe Sulfate
Slag
Pb Solder
PbSi04
PbO
PbMO
Native Pb
Paint
Mn Oxide
Fe Oxide
Cerassite
Brass
Barite
As203
~ Frequency
~ Mass
0%
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
100%
80% --
o
g
&
250
TM 5_Final.xls: VB-170 Figures
-------
Test Material 6 - Arsenic
Speciation Summary Statistics
Mineral
COUNTS
SIZE
Count Freq (%)
LW Freq (%)
Rel. As Mass (%)
Total
Lib
Avg
Min
Max
Total
Liberated
Total
Liberated
Total
Liberated
Clays
1
1
2
2
2
0.8%
0.8%
0.2%
0.2%
0.0%
0.0%
Anglesite
8
8
1
1
1
6.0%
6.0%
1.0%
1.0%
0.0%
0.0%
As203
30
30
8
2
26
22.6%
22.6%
28.2%
28.2%
80.1%
80.1%
AsMO
1
1
2
2
2
0.8%
0.8%
0.2%
0.2%
0.1%
0.1%
AsSbO
7
7
5
1
9
5.3%
5.3%
4.0%
4.0%
1.0%
1.0%
Fe Oxide
7
7
16
3
48
5.3%
5.3%
13.4%
13.4%
0.5%
0.5%
Galena
1
1
2
2
2
0.8%
0.8%
0.2%
0.2%
0.0%
0.0%
PbAsO
47
47
3
1
8
35.3%
35.3%
15.5%
15.5%
18.2%
18.2%
PbCr04
20
20
1
1
1
15.0%
15.0%
2.4%
2.4%
0.0%
0.0%
Pb Solder
1
1
15
15
15
0.8%
0.8%
1.8%
1.8%
0.0%
0.0%
Phosphate
2
2
8
1
14
1.5%
1.5%
1.8%
1.8%
0.1%
0.1%
Pyrite
1
1
4
4
4
0.8%
0.8%
0.5%
0.5%
0.0%
0.0%
Slag
7
7
37
20
58
5.3%
5.3%
30.8%
30.8%
0.0%
0.0%
TOTAL
133
133
6
91.7%
91.7%
100.00%
100.00%
100.0%
100.0%
TM 6 Final.xls
-------
Test Material 6 - Speciation and Particle Size Data
Panel A: Relative Arsenic Mass
Slag
Pyrite
Phosphate
Pb Solder
PbCr04
PbAsO
Galena
Fe Oxide
AsSbO
AsMO
As203
Anglesite
Clays
1
~ Frequency
~ Mass
P
0%
10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Panel B: Particle Size Distribution
100%
80% --
o
g
&
250
TM 6_Final.xls: VB-170 Figures
-------
APPENDIX B
DETAILED RESULTS FROM STUDY 1
-------
VB Experiment 1 Schedule
Study
Day
Cull Pigs/
Assign Dose Group
48 hr Urine
Collection
Sacrifice
Day
Date
Dose Administration
Feed
Weigh
Dose Prep
-4
Tuesday
9/14/1999
X
-3
Wednesday
9/15/1999
X
-2
Thursday
9/16/1999
X
-1
Friday
9/17/1999
X
X
X
X
0
Saturday
9/18/1999
X
X
1
Sunday
9/19/1999
X
X
2
Monday
9/20/1999
X
X
X
X
3
Tuesday
9/21/1999
X
X
4
Wednesday
9/22/1999
X
X
5
Thursday
9/23/1999
X
X
X
X
6
Friday
9/24/1999
X
X
j
k
7
Saturday
9/25/1999
X
X
r
8
Sunday
9/26/1999
X
X
X
X
i
k
9
Monday
9/27/1999
X
X
r
10
Tuesday
9/28/1999
X
X
i
k
11
Wednesday
9/29/1999
X
X
X
r
12
Thursday
9/30/1999
X
-------
809
828
831
815
821
825
842
826
827
835
841
802
804
807
813
819
822
834
840
801
812
823
836
806
811
816
820
803
808
810
833
818
829
830
832
VB1 Pig Group Assignments
group
dosage
material
1
0
None
50
NaAs
125
NaAs
50
Test Material 1
125
Test Material 1
50
Test Material 2
125
Test Material 2
8
8
8
8
50
Test Material 3
125
Test Material 3
VB1urinemast.xls
-------
TABLE B-1 BODY WEIGHTS AND ADMINISTERED DOSES, BY DAY
Body weights were measured on days -1, 2, 5, 8, 11. Weights for other days are estimated, based on linear interpolation between measured values.
Group
ID#
Day -1
Day 0
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Day 9
Day 10
Day 11
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
809
8.79
0
9.2
0
9.6
0
9.96
0
10.4
0
10.7
0
11.13
0
11.6
0
12.0
0
12.47
0
13.1
0
13.7
0
14.28
0
828
8.14
0
8.4
0
8.7
0
9.05
0
9.5
0
10.0
0
10.43
0
10.9
0
11.4
0
11.88
0
12.5
0
13.1
0
13.73
0
831
8.97
0
9.4
0
9.7
0
10.11
0
10.4
0
10.6
0
10.83
0
11.4
0
11.9
0
12.47
0
13.0
0
13.6
0
14.11
0
2
815
7.73
0
8.2
531
8.6
531
9.03
531
9.4
566
9.8
566
10.21
566
10.6
637
11.1
637
11.51
637
12.1
713
12.8
713
13.41
713
2
821
10.94
0
11.1
531
11.2
531
11.4
531
11.9
566
12.4
566
12.85
566
13.4
637
14.0
637
14.57
637
15.2
713
15.9
713
16.54
713
2
825
10.54
0
10.5
531
10.6
531
10.56
531
11.1
566
11.6
566
12.1
566
12.7
637
13.3
637
13.88
637
14.4
713
14.9
713
15.44
713
2
842
9.29
0
9.6
531
10.0
531
10.31
531
10.8
566
11.3
566
11.76
566
12.2
637
12.6
637
13.06
637
13.8
713
14.4
713
15.13
713
3
826
8.5
0
8.9
1223
9.4
1223
9.83
1223
10.3
1373
10.8
1373
11.34
1373
11.8
1548
12.3
1548
12.78
1548
13.5
1724
14.3
1724
15.02
1724
3
827
8.87
0
9.1
1223
9.3
1223
9.55
1223
10.0
1373
10.5
1373
11
1373
11.4
1548
11.9
1548
12.28
1548
12.8
1724
13.3
1724
13.82
1724
3
835
9.44
0
9.8
1223
10.1
1223
10.47
1223
10.9
1373
11.4
1373
11.84
1373
12.3
1548
12.8
1548
13.29
1548
14.0
1724
14.8
1724
15.52
1724
3
841
8.31
0
8.9
1223
9.5
1223
10.07
1223
10.5
1373
10.9
1373
11.37
1373
11.9
1548
12.3
1548
12.82
1548
13.5
1724
14.2
1724
14.82
1724
4
802
9.24
0
9.47
394
9.7
394
9.92
394
10.4
419
10.9
419
11.45
419
11.8
466
12.1
466
12.46
466
13.4
526
14.3
526
15.19
526
4
804
10.83
0
11.0
394
11.2
394
11.4
394
11.7
419
12.0
419
12.33
419
13.0
466
13.6
466
14.28
466
14.7
526
15.2
526
15.62
526
4
807
10.26
0
10.4
394
10.6
394
10.82
394
11.3
419
11.8
367
12.3
335
12.9
280
13.5
292
14.1
373
14.5
474
14.8
526
15.15
526
4
813
8.29
0
8.6
394
8.9
394
9.23
394
9.6
419
10.0
419
10.39
419
11.0
466
11.5
466
12.09
466
12.8
526
13.5
526
14.16
526
5
819
8.45
0
9.0
860
9.5
860
10.08
860
10.4
960
10.7
960
10.96
960
11.4
1102
11.9
1102
12.36
1102
13.2
1208
14.1
1208
15.01
1208
5
822
9.34
0
9.6
860
9.8
860
10.06
860
10.7
960
11.4
960
12.06
960
12.3
1102
12.6
1102
12.89
1102
13.6
1208
14.3
1208
15.01
1208
5
834
7.39
0
7.8
860
8.2
860
8.57
860
9.0
960
9.4
960
9.84
960
10.2
1102
10.5
1102
10.87
1102
11.6
1208
12.3
1208
13
1208
5
840
8.03
0
8.3
860
8.6
860
8.84
860
9.5
960
10.2
960
10.82
960
11.3
1102
11.7
1102
12.18
1102
12.8
1208
13.5
1208
14.15
1208
6
801
7.97
0
8.5
307
9.0
307
9.45
307
9.7
334
9.9
334
10.08
334
10.7
372
11.3
372
11.84
372
12.5
428
13.1
428
13.8
428
6
812
7.42
0
7.9
307
8.4
307
8.92
307
9.4
334
9.8
334
10.21
334
10.8
372
11.3
372
11.88
372
12.4
428
13.0
428
13.52
428
6
823
9.12
0
8.7
307
8.3
307
7.82
307
8.3
167
8.7
300
9.12
267
9.7
223
10.3
270
10.96
298
11.7
385
12.5
428
13.2
428
6
836
7.76
0
8.2
307
8.7
307
9.17
307
9.6
334
10.1
334
10.5
334
10.9
372
11.4
372
11.82
372
12.3
428
12.8
428
13.22
428
7
806
8.19
0
8.8
815
9.4
815
10.05
815
10.5
939
10.9
939
11.34
939
11.7
1034
12.1
1034
12.49
1034
13.2
1132
14.0
1132
14.76
1132
7
811
10.14
0
10.5
815
10.9
815
11.23
815
11.8
939
12.3
939
12.83
939
13.1
1034
13.5
1034
13.78
1034
13.9
1132
14.0
1132
14.16
1132
7
816
8.13
0
8.5
815
8.8
815
9.17
652
9.4
939
9.7
751
10
704
10.4
620
10.8
646
11.18
827
11.9
1018
12.6
1132
13.29
1132
7
820
8
0
8.6
815
9.2
815
9.85
815
10.1
939
10.4
939
10.64
939
11.1
1034
11.5
1034
11.96
1034
12.7
1132
13.4
1132
14.14
1132
8
803
8.22
0
8.7
268
9.1
268
9.54
268
10.1
311
10.6
311
11.1
311
11.7
346
12.4
346
12.99
346
13.5
388
14.0
388
14.52
388
8
808
9.08
0
9.6
268
10.1
268
10.56
268
11.1
311
11.6
311
12.05
311
12.5
346
12.9
346
13.38
346
14.1
388
14.7
388
15.39
388
8
810
8.89
0
9.5
268
10.1
268
10.76
268
11.0
311
11.3
311
11.56
311
12.0
346
12.5
346
12.98
346
13.7
388
14.5
388
15.25
388
8
833
8.9
0
9.4
268
10.0
268
10.48
268
10.9
311
11.3
311
11.75
311
12.2
346
12.7
346
13.12
346
13.9
388
14.8
388
15.6
388
9
818
9.44
0
10.0
748
10.6
748
11.16
748
11.7
852
12.3
852
12.81
852
13.2
943
13.6
943
13.93
943
14.5
1026
15.2
1026
15.78
1026
9
829
9.87
0
10.4
748
11.0
748
11.49
748
12.0
852
12.5
852
12.95
852
13.3
943
13.6
943
13.98
943
14.6
1026
15.3
1026
15.94
1026
9
830
10.62
0
11.1
748
11.5
748
12.01
748
12.4
852
12.7
852
13.08
852
13.5
943
13.9
943
14.32
943
15.0
1026
15.7
1026
16.35
1026
9
832
9.65
0
10.1
748
10.6
748
11
748
11.4
852
11.7
852
12.1
852
12.6
943
13.0
943
13.52
943
14.2
1026
14.9
1026
15.63
1026
Day
2-Pig
816
did
not
eat
ent
re
Day
3-Pig
823
did
not
eat
ent
re
Day
4-Pig
823
did
not
eat
ent
re
Day
4-Pig
816
did
not
eat
ent
re
Day
4-Pig
807
did
not
eat
ent
re
Day
5-Pig
823
did
not
eat
ent
re
Day
5-Pig
807
did
not
eat
ent
re
Day
5-Pig
816
did
not
eat
ent
re
Day
6-Pig
823
did
not
eat
ent
re
Day
6-Pig
807
did
not
eat
ent
re
Day
6-Pig
816
did
not
eat
ent
re
Day
7-Pig
823
did
not
eat
ent
re
Day
7-Pig
807
did
not
eat
ent
re
Day
7-Pig
816
did
not
eat
ent
re
Day
8-Pig
823
did
not
eat
ent
re
Day
8-Pig
807
did
not
eat
ent
re
Day
8-Pig
816
did
not
eat
ent
re
Day
9-Pig
823
did
not
eat
ent
re
Day
9-Pig
807
did
not
eat
ent
re
Day
9-Pig
816
did
not
eat
ent
re
; afternoon dose (ate approximately 60%). Daily dose adjusted to 80%
; morningn dose. Daily dose adjusted to 50%
; afternoon dose (ate approximately 80%). Daily dose adjusted to 90%
; morning dose (ate approximately 60%). Daily dose adjusted to 80%
; afternoon dose (ate approximately 75%). Daily dose adjusted to 87.5%
; morning dose (ate approximately 60%). Daily dose adjusted to 80%
; morning dose (ate approximately 60%). Daily dose adjusted to 80%
; morning dose (ate approximately 50%). Daily dose adjusted to 75%
; morning or afternoon dose (ate approximately 60% of each). Daily dose adjusted to 60%
; morning or afternoon dose (ate approximately 60% of each). Daily dose adjusted to 60%
; morning or afternoon dose (ate approximately 60% of each). Daily dose adjusted to 60%
; morning or afternoon dose (ate approximately 85% & 60%, respectively). Daily dose adjusted to 72.5%
; morning or afternoon dose (ate approximately 75% & 50%, respectively). Daily dose adjusted to 62.5%
; morning or afternoon dose (ate approximately 65% & 60%, respectively). Daily dose adjusted to 62.5%
; morning dose (ate approximately 60%). Daily dose adjusted to 80%
; morning dose (ate approximately 60%). Daily dose adjusted to 80%
; morning dose (ate approximately 60%). Daily dose adjusted to 80%
; morning or afternoon dose (ate approximately 90% of each). Daily dose adjusted to 90%
; morning or afternoon dose (ate approximately 90% of each). Daily dose adjusted to 90%
; morning or afternoon dose (ate approximately 90% of each). Daily dose adjusted to 90%
Page 1
-------
TABLE B-2
Body Weight Adjusted Doses (ug/kg-day]
(Dose for Day/BW for Day)
Group
ID#
Day 0
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Day 9
Day 10
Day 11
Avg Dose Target Dose
% Target
Avg %
1
809
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0
1
828
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0
1
831
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0
2
815
65.08
61.80
58.83
60.09
57.68
55.46
59.80
57.46
55.30
58.69
55.79
53.15
58.26
50
117
2
821
47.89
47.24
46.60
47.65
45.79
44.07
47.42
45.48
43.69
46.81
44.87
43.09
45.88
50
92
2
825
50.37
50.34
50.31
51.14
48.87
46.80
50.14
47.91
45.86
49.50
47.77
46.16
48.76
50
98
2
842
55.17
53.28
51.53
52.46
50.21
48.15
52.20
50.41
48.74
51.84
49.36
47.11
50.87
50
102
102
3
826
136.69
130.24
124.36
132.82
126.65
121.03
131.00
125.89
121.16
127.46
120.79
114.78
126.07
125
101
3
827
134.39
131.12
128.01
136.79
130.51
124.77
135.51
130.63
126.09
134.76
129.56
124.75
130.58
125
104
3
835
124.96
120.72
116.76
125.61
120.57
115.92
125.65
120.91
116.51
122.85
116.67
111.09
119.85
125
96
3
841
137.41
128.91
121.40
130.67
125.50
120.71
130.63
125.52
120.78
127.83
121.81
116.33
125.63
125
101
100
4
802
41.61
40.63
39.71
40.20
38.33
36.62
39.57
38.47
37.43
39.35
36.84
34.64
38.62
50
77
4
804
35.74
35.14
34.55
35.81
34.88
34.01
35.93
34.22
32.66
35.73
34.67
33.68
34.75
50
70
4
807
37.70
37.04
36.40
37.06
31.07
27.27
21.69
21.59
26.46
32.77
35.55
34.73
31.61
50
63
4
813
45.78
44.17
42.67
43.60
41.92
40.36
42.57
40.48
38.58
41.17
39.06
37.16
41.46
50
83
73
5
819
95.59
90.15
85.29
92.54
90.00
87.59
96.41
92.62
89.13
91.24
85.54
80.50
89.72
125
72
5
822
89.74
87.55
85.46
89.49
84.26
79.60
89.30
87.34
85.46
88.87
84.48
80.50
86.00
125
69
5
834
110.46
105.14
100.32
106.74
101.95
97.56
108.18
104.65
101.34
104.35
98.32
92.95
102.66
125
82
5
840
103.58
100.32
97.25
101.05
94.49
88.72
97.72
93.94
90.44
94.13
89.55
85.40
94.72
125
76
75
6
801
36.32
34.32
32.52
34.53
33.79
33.09
34.88
33.07
31.43
34.25
32.55
31.01
33.48
50
67
6
812
38.81
36.50
34.46
35.67
34.10
32.67
34.56
32.86
31.32
34.44
32.99
31.65
34.17
50
68
6
823
35.38
37.24
39.30
20.21
34.56
29.26
22.94
26.07
27.16
32.90
34.36
32.42
30.98
50
62
6
836
37.35
35.33
33.52
34.70
33.17
31.77
34.01
32.70
31.48
34.83
33.56
32.37
33.73
50
67
66
7
806
92.48
86.40
81.07
89.55
86.02
82.76
88.21
85.41
82.79
85.42
80.80
76.66
84.80
125
68
7
811
77.57
74.98
72.55
79.78
76.32
73.15
78.66
76.81
75.04
81.36
80.63
79.91
77.23
125
62
7
816
96.12
92.34
71.08
99.35
77.22
70.39
59.70
59.92
73.99
85.70
89.90
85.14
80.07
125
64
7
820
94.56
88.24
82.72
92.80
90.44
88.21
93.33
89.76
86.46
89.19
84.36
80.02
88.34
125
71
66
8
803
30.99
29.49
28.13
30.95
29.42
28.05
29.54
28.03
26.67
28.72
27.68
26.70
28.70
50
57
8
808
28.04
26.66
25.42
28.16
26.95
25.84
27.73
26.78
25.89
27.60
26.34
25.19
26.72
50
53
8
810
28.21
26.48
24.94
28.23
27.57
26.93
28.79
27.70
26.69
28.23
26.75
25.43
27.16
50
54
8
833
28.47
26.97
25.61
28.55
27.48
26.49
28.38
27.36
26.41
27.80
26.25
24.85
27.05
50
54
55
9
818
74.71
70.66
67.03
72.80
69.53
66.54
71.54
69.57
67.70
70.51
67.64
65.00
69.43
125
56
9
829
71.86
68.32
65.11
71.17
68.40
65.83
70.94
69.16
67.46
70.09
67.09
64.34
68.31
125
55
9
830
67.50
64.79
62.29
68.93
67.00
65.17
69.89
67.81
65.86
68.39
65.44
62.73
66.32
125
53
9
832
74.07
70.91
68.01
74.99
72.65
70.45
75.01
72.28
69.75
72.11
68.71
65.62
71.21
125
57
55
Page 1
-------
TABLE B-3 VB Experiment 1 Urine Volumes - 48 hour collections
Units of Volume: mis
Day
Group
Pig ID
6-7
8-9
10-11
9/24-9/26
9/26-9/28
9/28-9/30
1
809
9740
9100
15100
828
2240
2860
3420
831
1320
1330
2430
2
815
2320
1690
1820
821
2250
1500
3700
825
3510
2790
3840
842
2700
2430
5000
3
826
15340
20320
22360
827
6690
8300
8320
835
2190
2970
4360
841
2220
3860
2500
4
802
9490
11310
7820
804
13210
6920
4200
807
1050
1190
2200
813
1900
1560
2300
5
819
9310
1110
3680
822
4520
2680
3200
834
6540
7460
3900
840
4290
4190
4820
6
801
19790
17860
10300
812
890
900
1000
823
2640
2520
3360
836
10880
11660
7660
7
806
5610
4000
2800
811
4160
2360
2440
816
4250
7120
4020
820
13820
15000
14800
8
803
3640
5820
6560
808
2980
3000
3700
810
2830
3780
7060
833
5320
6660
6580
9
818
2300
3340
4000
829
2440
2480
2000
830
3320
2560
3100
832
3790
3540
2980
Volume measured by:
DD
DD/MD
KM
Date:
9/26/1999
9/26/1999
9/30/1999
Diarrhea urines: 819-see above 804-1320mls
Ones with volumes 810-510ml
were kept separate.
VB1urinemast.xls
-------
TABLE B-4 URINE ANALYTICAL RESULTS
tag number
pig number
day
group
material administered dosage Q
Urine Cone Ur
VB-01-00049
809
6/7
1
Control
0
14 ng/m
VB-01 -00044
828
6/7
1
Control
0
46 ng/m
VB-01-00050
831
6/7
1
Control
0
78 ng/m
VB-01-00061
815
6/7
2
NaAs
50
790 ng/m
VB-01-00051
821
6/7
2
NaAs
50
1000 ng/m
VB-01-00047
825
6/7
2
NaAs
50
950 ng/m
VB-01-00034
842
6/7
2
NaAs
50
920 ng/m
VB-01-00048
826
6/7
3
NaAs
125
170 ng/m
VB-01-00045
827
6/7
3
NaAs
125
360 ng/m
VB-01-00070
835
6/7
3
NaAs
125
1200 ng/m
VB-01-00038
841
6/7
3
NaAs
125
690 ng/m
VB-01-00042
802
6/7
4
TM1
50
44 ng/m
VB-01-00054
804
6/7
4
TM1
50
37 ng/m
VB-01-00035
807
6/7
4
TM1
50
380 ng/m
VB-01-00033
813
6/7
4
TM1
50
200 ng/m
VB-01-00039
819
6/7
5
TM1
125
73 ng/m
VB-01-00053
822
6/7
5
TM1
125
120 ng/m
VB-01-00043
834
6/7
5
TM1
125
120 ng/m
VB-01-00036
840
6/7
5
TM1
125
180 ng/m
VB-01-00064
801
6/7
6
TM2
50
16 ng/m
VB-01-00052
812
6/7
6
TM2
50
440 ng/m
VB-01-00062
823
6/7
6
TM2
50
67 ng/m
VB-01-00069
836
6/7
6
TM2
50
27 ng/m
VB-01-00063
806
6/7
7
TM2
125
120 ng/m
VB-01-00055
811
6/7
7
TM2
125
180 ng/m
VB-01-00031
816
6/7
7
TM2
125
120 ng/m
VB-01-00060
820
6/7
7
TM2
125
61 ng/m
VB-01-00046
803
6/7
8
TM3
50
81 ng/m
VB-01-00071
808
6/7
8
TM3
50
86 ng/m
VB-01-00066
810
6/7
8
TM3
50
77 ng/m
VB-01-00041
833
6/7
8
TM3
50
61 ng/m
VB-01-00056
818
6/7
9
TM3
125
170 ng/m
VB-01-00059
829
6/7
9
TM3
125
180 ng/m
VB-01-00068
830
6/7
9
TM3
125
160 ng/m
VB-01-00040
832
6/7
9
TM3
125
190 ng/m
VB-01-00058
2830
6/7
9
TM3
125
160 ng/m
VB-01-00067
2826
6/7
3
NaAs
125
160 ng/m
VB-01-00057
2801
6/7
6
TM2
50
16 ng/m
VB-01-00065
AsCtrl
6/7
19 ng/m
VB-01-00032
AslA100
6/7
120 ng/m
VB-01-00037
AslBlOO
6/7
110 ng/m
VB-01-00304
AsOAlOO
6/7
79 ng/m
VB-01-00305
AsOBlOO
6/7
93 ng/m
VB-01-00306
AslA25
6/7
43 ng/m
VB-01-00307
AslB25
6/7
40 ng/m
VB-01-00308
AsOA25
6/7
34 ng/m
VB-01-00309
AsOB25
6/7
38 ng/m
VB-01-00090
809
8/9
1
Control
0
8 ng/m
VB-01-00109
828
8/9
1
Control
0
41 ng/m
VB-01-00098
831
8/9
1
Control
0
80 ng/m
VB1 urinemast.xls
-------
| tag number
| pig number
I day
I group
| material administered! dosage| Q
Urine Cone | Ui
VB-01-00099
815
8/9
2
NaAs
50
920 ng/m
VB-01 -00077
821
8/9
2
NaAs
50
1200 ng/m
VB-01-00110
825
8/9
2
NaAs
50
790 ng/m
VB-01-00105
842
8/9
2
NaAs
50
840 ng/m
VB-01-00104
826
8/9
3
NaAs
125
160 ng/m
VB-01-00075
827
8/9
3
NaAs
125
300 ng/m
VB-01-00085
835
8/9
3
NaAs
125
870 ng/m
VB-01-00095
841
8/9
3
NaAs
125
760 ng/m
VB-01-00096
802
8/9
4
TM1
50
68 ng/m
VB-01-00106
804
8/9
4
TM1
50
32 ng/m
VB-01-00086
807
8/9
4
TM1
50
390 ng/m
VB-01-00091
813
8/9
4
TM1
50
260 ng/m
VB-01-00074
819
8/9
5
TM1
125
95 ng/m
VB-01-00112
822
8/9
5
TM1
125
290 ng/m
VB-01-00101
834
8/9
5
TM1
125
130 ng/m
VB-01-00087
840
8/9
5
TM1
125
210 ng/m
VB-01-00083
801
8/9
6
TM2
50
24 ng/m
VB-01-00081
812
8/9
6
TM2
50
420 ng/m
VB-01-00107
823
8/9
6
TM2
50
130 ng/m
VB-01-00108
836
8/9
6
TM2
50
36 ng/m
VB-01-00092
806
8/9
7
TM2
125
200 ng/m
VB-01-00089
811
8/9
7
TM2
125
360 ng/m
VB-01-00079
816
8/9
7
TM2
125
120 ng/m
VB-01-00088
820
8/9
7
TM2
125
65 ng/m
VB-01-00100
803
8/9
8
TM3
50
59 ng/m
VB-01-00072
808
8/9
8
TM3
50
110 ng/m
VB-01-00084
810
8/9
8
TM3
50
98 ng/m
VB-01-00094
833
8/9
8
TM3
50
56 ng/m
VB-01-00111
818
8/9
9
TM3
125
200 ng/m
VB-01-00093
829
8/9
9
TM3
125
220 ng/m
VB-01-00103
830
8/9
9
TM3
125
290 ng/m
VB-01-00082
832
8/9
9
TM3
125
230 ng/m
VB-01-00076
2836
8/9
6
TM2
50
35 ng/m
VB-01-00080
2821
8/9
2
NaAs
50
1200 ng/m
VB-01-00073
2804
8/9
4
TM1
50
33 ng/m
VB-01-00102
AsCtrl
8/9
19 ng/m
VB-01-00097
AslA100
8/9
120 ng/m
VB-01-00078
AslBlOO
8/9
120 ng/m
VB-01-00310
AsOAlOO
8/9
80 ng/m
VB-01-00311
AsOBlOO
8/9
93 ng/m
VB-01-00312
AslA25
8/9
44 ng/m
VB-01-00313
AslB25
8/9
42 ng/m
VB-01-00314
AsOA25
8/9
33 ng/m
VB-01-00315
AsOB25
8/9
38 ng/m
VB-01-00125
809
10/11
1
Control
0
10 ng/m
VB-01-00137
828
10/11
1
Control
0
37 ng/m
VB-01-00127
831
10/11
1
Control
0
52 ng/m
VB-01-00124
815
10/11
2
NaAs
50
520 ng/m
VB-01-00147
821
10/11
2
NaAs
50
370 ng/m
VB-01-00134
825
10/11
2
NaAs
50
400 ng/m
VB-01-00116
842
10/11
2
NaAs
50
300 ng/m
VB-01-00129
826
10/11
3
NaAs
125
150 ng/m
VB1 urinemast.xls
-------
tag number
| pig number
1 day
I group
| material administered! dosage| Q
Urine Cone | Units
VB-01-00143
827
10/11
3
NaAs
125
210 ng/mL
VB-01-00133
835
10/11
3
NaAs
125
400 ng/mL
VB-01-00114
841
10/11
3
NaAs
125
1100 ng/mL
VB-01-00126
802
10/11
4
TM1
50
11 ng/mL
VB-01-00139
804
10/11
4
TM1
50
120 ng/mL
VB-01-00128
807
10/11
4
TM1
50
270 ng/mL
VB-01-00149
813
10/11
4
TM1
50
160 ng/mL
VB-01-00138
819
10/11
5
TM1
125
110 ng/mL
VB-01-00152
822
10/11
5
TM1
125
300 ng/mL
VB-01-00117
834
10/11
5
TM1
125
140 ng/mL
VB-01-00141
840
10/11
5
TM1
125
200 ng/mL
VB-01-00113
801
10/11
6
TM2
50
24 ng/mL
VB-01-00120
812
10/11
6
TM2
50
500 ng/mL
VB-01-00123
823
10/11
6
TM2
50
96 ng/mL
VB-01-00146
836
10/11
6
TM2
50
32 ng/mL
VB-01-00151
806
10/11
7
TM2
125
250 ng/mL
VB-01-00148
811
10/11
7
TM2
125
350 ng/mL
VB-01-00135
816
10/11
7
TM2
125
88 ng/mL
VB-01-00118
820
10/11
7
TM2
125
65 ng/mL
VB-01-00122
803
10/11
8
TM3
50
55 ng/mL
VB-01-00136
808
10/11
8
TM3
50
94 ng/mL
VB-01-00144
810
10/11
8
TM3
50
53 ng/mL
VB-01-00119
833
10/11
8
TM3
50
64 ng/mL
VB-01-00153
818
10/11
9
TM3
125
180 ng/mL
VB-01-00121
829
10/11
9
TM3
125
280 ng/mL
VB-01-00132
830
10/11
9
TM3
125
210 ng/mL
VB-01-00131
832
10/11
9
TM3
125
220 ng/mL
VB-01-00150
2811
10/11
7
TM2
125
360 ng/mL
VB-01-00140
2842
10/11
2
NaAs
50
200 ng/mL
VB-01-00130
2802
10/11
4
TM1
50
12 ng/mL
VB-01-00142
AsCtrl
10/11
19 ng/mL
VB-01-00115
AslA100
10/11
120 ng/mL
VB-01-00145
AslBlOO
10/11
120 ng/mL
VB-01-00316
AsOAlOO
10/11
80 ng/mL
VB-01-00317
AsOBlOO
10/11
91 ng/mL
VB-01-00318
AslA25
10/11
44 ng/mL
VB-01-00319
AslB25
10/11
42 ng/mL
VB-01 -00320
AsOA25
10/11
34 ng/mL
VB-01-00321
AsOB25
10/11
37 ng/mL
VB-01-00322
AsMixl
-99
93 ng/mL
VB-01-00323
AsMix2
-99
38 ng/mL
VB-01-00324
AsMix3
-99
23 ng/mL
VB1 urinemast.xls
-------
TABLE B-5 VB Experiment 1 Fecal Weights - 48 hour collections
Units of Weight: grams
Day
Group
Pig ID
6-7
8-9
10-11
9/24-9/26
9/26-9/28
9/28-9/30
1
809
295.61
218.99
261.17
828
198.25
191.25
188
831
216.61
118.64
262.91
2
815
147.44
107.92
274.15
821
145.06
128.51
351.98
825
129.99
266.4
276.38
842
274.67
185.7
283.33
3
826
199.69
189.51
220.02
827
229.99
225.15
180.77
835
304.87
235.9
406.71
841
215.65
246.15
256.68
4
802
222.6
322.21
246.59
804
199.52
270.14
287.04
807
214.37
127.28
248.76
813
287.64
64.05
155.44
5
819
320.06
184.76
305.67
822
375.46
401.48
329.43
834
309.24
342.81
471.02
840
308.47
195.08
338.68
6
801
185.23
310.07
231
812
342.87
292.14
403.56
823
263.49
221.76
861.03
836
326.16
293.89
377.69
7
806
310.95
207.28
291.17
811
280.08
269.37
457.79
816
166.77
208.12
354.04
820
328.65
177.66
307.77
8
803
192.44
314.75
393.19
808
388.13
352.86
267.33
810
426.34
240.72
487.79
833
265.66
289.35
486.25
9
818
302.95
285.9
443.79
829
223.93
152.02
338.55
830
294.09
206.98
317.78
832
419.49
222.97
303.41
Weighed by:
FW
FW
DED
Date:
36431
36431
36434
VB1fecesmast.xls
-------
TABLE B-6 FECES ANALYTICAL RESULTS
tag number
pig number
day
group
material administered dosage Q
Feces Cone
Units
VB-01-00162
809
6/7
1
Control
0
90
ng/g
VB-01-00158
828
6/7
1
Control
0
280
ng/g
VB-01-00189
831
6/7
1
Control
0
130
ng/g
VB-01-00168
815
6/7
2
NaAs
50
440
ng/g
VB-01-00179
821
6/7
2
NaAs
50
450
ng/g
VB-01-00164
825
6/7
2
NaAs
50
270
ng/g
VB-01-00184
842
6/7
2
NaAs
50
490
ng/g
VB-01-00159
826
6/7
3
NaAs
125
1900
ng/g
VB-01-00176
827
6/7
3
NaAs
125
330
ng/g
VB-01-00181
835
6/7
3
NaAs
125
230
ng/g
VB-01-00157
841
6/7
3
NaAs
125
330
ng/g
VB-01-00191
802
6/7
4
TM1
50
1800
ng/g
VB-01-00154
804
6/7
4
TM1
50
1600
ng/g
VB-01-00169
807
6/7
4
TM1
50
730
ng/g
VB-01-00178
813
6/7
4
TM1
50
1000
ng/g
VB-01-00156
819
6/7
5
TM1
125
2000
ng/g
VB-01-00165
822
6/7
5
TM1
125
2500
ng/g
VB-01-00155
834
6/7
5
TM1
125
3100
ng/g
VB-01-00186
840
6/7
5
TM1
125
3200
ng/g
VB-01-00161
801
6/7
6
TM2
50
970
ng/g
VB-01-00172
812
6/7
6
TM2
50
950
ng/g
VB-01-00166
823
6/7
6
TM2
50
660
ng/g
VB-01-00170
836
6/7
6
TM2
50
1100
ng/g
VB-01-00167
806
6/7
7
TM2
125
3300
ng/g
VB-01-00188
811
6/7
7
TM2
125
3500
ng/g
VB-01-00173
816
6/7
7
TM2
125
1900
ng/g
VB-01-00171
820
6/7
7
TM2
125
3800
ng/g
VB-01-00190
803
6/7
8
TM3
50
720
ng/g
VB-01-00174
808
6/7
8
TM3
50
480
ng/g
VB-01-00187
810
6/7
8
TM3
50
400
ng/g
VB-01-00180
833
6/7
8
TM3
50
670
ng/g
VB-01-00160
818
6/7
9
TM3
125
1500
ng/g
VB-01-00177
829
6/7
9
TM3
125
1600
ng/g
VB-01-00185
830
6/7
9
TM3
125
1100
ng/g
VB-01-00175
832
6/7
9
TM3
125
1500
ng/g
VB-01-00163
2834
6/7
5
TM1
125
2200
ng/g
VB-01-00183
2816
6/7
7
TM2
125
2400
ng/g
VB-01-00182
2802
6/7
4
TM1
50
1300
ng/g
VB-01-00193
809
8/9
1
Control
0
160
ng/g
VB-01 -00208
828
8/9
1
Control
0
200
ng/g
VB-01-00219
831
8/9
1
Control
0
210
ng/g
VB-01-00227
815
8/9
2
NaAs
50
910
ng/g
VB-01-00220
821
8/9
2
NaAs
50
1300
ng/g
VB-01-00222
825
8/9
2
NaAs
50
370
ng/g
VB-01-00203
842
8/9
2
NaAs
50
1100
ng/g
VB-01-00194
826
8/9
3
NaAs
125
900
ng/g
VB-01-00216
827
8/9
3
NaAs
125
380
ng/g
VB-01-00206
835
8/9
3
NaAs
125
620
ng/g
VB-01-00217
841
8/9
3
NaAs
125
340
ng/g
VB-01-00229
802
8/9
4
TM1
50
1400
ng/g
VB1fecesmast.xls
-------
tag number
| pig number |
day |
group
| material administered! dosage| Q
| Feces Cone |
Units |
VB-01-00215
804
8/9
4
TM1
50
1400
ng/g
VB-01-00198
807
8/9
4
TM1
50
1100
ng/g
VB-01-00213
813
8/9
4
TM1
50
2100
ng/g
VB-01-00202
819
8/9
5
TM1
125
2200
ng/g
VB-01-00210
822
8/9
5
TM1
125
2100
ng/g
VB-01-00228
834
8/9
5
TM1
125
7900
ng/g
VB-01-00211
840
8/9
5
TM1
125
2900
ng/g
VB-01-00201
801
8/9
6
TM2
50
900
ng/g
VB-01-00192
812
8/9
6
TM2
50
720
ng/g
VB-01-00218
823
8/9
6
TM2
50
930
ng/g
VB-01-00207
836
8/9
6
TM2
50
1500
ng/g
VB-01-00195
806
8/9
7
TM2
125
4500
ng/g
VB-01-00196
811
8/9
7
TM2
125
2300
ng/g
VB-01-00197
816
8/9
7
TM2
125
1700
ng/g
VB-01-00226
820
8/9
7
TM2
125
3000
ng/g
VB-01-00221
803
8/9
8
TM3
50
510
ng/g
VB-01-00223
808
8/9
8
TM3
50
1300
ng/g
VB-01-00225
810
8/9
8
TM3
50
540
ng/g
VB-01-00199
833
8/9
8
TM3
50
790
ng/g
VB-01-00205
818
8/9
9
TM3
125
1500
ng/g
VB-01-00209
829
8/9
9
TM3
125
2000
ng/g
VB-01-00224
830
8/9
9
TM3
125
2700
ng/g
VB-01-00214
832
8/9
9
TM3
125
1400
ng/g
VB-01-00200
2801
8/9
6
TM2
50
1000
ng/g
VB-01-00204
2813
8/9
4
TM1
50
2500
ng/g
VB-01-00212
2820
8/9
7
TM2
125
3400
ng/g
VB-01-00267
809
10/11
1
Control
0
160
ng/g
VB-01-00248
828
10/11
1
Control
0
170
ng/g
VB-01-00264
831
10/11
1
Control
0
190
ng/g
VB-01-00244
815
10/11
2
NaAs
50
370
ng/g
VB-01-00242
821
10/11
2
NaAs
50
400
ng/g
VB-01-00259
825
10/11
2
NaAs
50
240
ng/g
VB-01-00230
842
10/11
2
NaAs
50
510
ng/g
VB-01-00254
826
10/11
3
NaAs
125
2600
ng/g
VB-01-00262
827
10/11
3
NaAs
125
410
ng/g
VB-01-00233
835
10/11
3
NaAs
125
420
ng/g
VB-01-00255
841
10/11
3
NaAs
125
520
ng/g
VB-01-00250
802
10/11
4
TM1
50
1700
ng/g
VB-01-00253
804
10/11
4
TM1
50
1500
ng/g
VB-01-00240
807
10/11
4
TM1
50
1100
ng/g
VB-01-00236
813
10/11
4
TM1
50
1800
ng/g
VB-01-00252
819
10/11
5
TM1
125
3400
ng/g
VB-01-00257
822
10/11
5
TM1
125
2400
ng/g
VB-01-00237
834
10/11
5
TM1
125
2000
ng/g
VB-01-00258
840
10/11
5
TM1
125
2600
ng/g
VB-01-00235
801
10/11
6
TM2
50
1400
ng/g
VB-01-00251
812
10/11
6
TM2
50
2100
ng/g
VB-01-00241
823
10/11
6
TM2
50
620
ng/g
VB-01-00265
836
10/11
6
TM2
50
1100
ng/g
VB-01-00243
806
10/11
7
TM2
125
3500
ng/g
VB-01-00260
811
10/11
7
TM2
125
2400
ng/g
VB-01-00234
816
10/11
7
TM2
125
2500
ng/g
VB1fecesmast.xls
-------
tag number
| pig number |
day |
group
| material administered! dosage| Q
| Feces Cone |
Units |
VB-01-00249
820
10/11
7
TM2
125
4000
ng/g
VB-01 -00266
803
10/11
8
TM3
50
750
ng/g
VB-01-00239
808
10/11
8
TM3
50
1300
ng/g
VB-01-00231
810
10/11
8
TM3
50
660
ng/g
VB-01-00238
833
10/11
8
TM3
50
650
ng/g
VB-01-00232
818
10/11
9
TM3
125
2100
ng/g
VB-01-00246
829
10/11
9
TM3
125
2200
ng/g
VB-01-00263
830
10/11
9
TM3
125
2900
ng/g
VB-01-00261
832
10/11
9
TM3
125
2600
ng/g
VB-01-00245
2822
10/11
5
TM1
125
3200
ng/g
VB-01-00247
2818
10/11
9
TM3
125
1700
ng/g
VB-01-00256
2827
10/11
3
NaAs
125
840
ng/g
VB1fecesmast.xls
-------
APPENDIX C
DETAILED RESULTS FROM STUDY 2
-------
VB Experiment 2 Schedule
Study
Day
Cull Pigs/
jn Dose C
48 hr Urine
Collection
Sacrifice
Day
Date
Dose Administration
Feed
Weigh
Dose Prep
-4
Tuesday
9/28/99
X
-3
Wednesday
9/29/1999
X
-2
Thursday
9/30/1999
X
X
-1
Friday
10/1/1999
X
X
X
24-hr Collection
0
Saturday
10/2/1999
X
X
1
Sunday
10/3/1999
X
X
2
Monday
10/4/1999
X
X
X
X
3
Tuesday
10/5/1999
X
X
4
Wednesday
10/6/1999
X
X
5
Thursday
10/7/1999
X
X
X
X
6
Friday
10/8/1999
X
X
ik
7
Saturday
10/9/1999
X
X
V
8
Sunday
10/10/1999
X
X
X
X
i
k
9
Monday
10/11/1999
X
X
r
10
Tuesday
10/12/1999
X
X
k
k
11
Wednesday
10/13/1999
X
X
X
r
12
Thursday
10/14/1999
X
VB2urinemast.xls
-------
VB2 Pig Group Assignments
pig number
group
dosage
material
903
1
0
None
935
1
940
1
902
2
50
NaAs
910
2
911
2
938
2
909
3
125
NaAs
912
3
925
3
936
3
918
4
50
Test Material 4
929
4
932
4
937
4
913
5
125
Test Material 4
914
5
919
5
939
5
901
6
50
Test Material 5
922
6
930
6
933
6
915
7
125
Test Material 5
921
7
924
7
934
7
905
8
50
Test Material 6
917
8
920
8
927
8
904
9
125
Test Material 6
908
9
926
9
931
9
VB2urinemast.xls
-------
TABLE C-1 BODY WEIGHTS AND ADMINISTERED DOSES, BY DAY
Body weights were measured on days -1, 2, 5, 8, 11. Weights for other days are estimated, based on linear interpolation between measured values.
Group
ID#
Day -1
Day 0
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Day 9
Day 10
Day 11 I
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As
BW
ug As |
(kg)
per day
(kg) per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
(kg)
per day
1
903
8.13
0
8.3
0
8.5
0
8.62
0
9.0
0
9.4
0
9.81
0
10.3
0
10.7
0
11.2
0
11.5
0
11.8
0
12.14
0
1
935
7.56
0
7.8
0
8.1
0
8.34
0
8.6
0
8.8
0
9.03
0
9.4
0
9.7
0
10.09
0
10.6
0
11.2
0
11.68
0
1
940
6.81
0
7.0
0
7.1
0
7.25
0
7.8
0
8.3
0
8.89
0
9.1
0
9.4
0
9.64
0
10.1
0
10.6
0
11.11
0
2
902
7.17
0
7.5
384
7.8
384
8.16
384
8.4
418
8.7
418
8.94
418
9.3
452
9.7
452
10.05
452
10.4
516
10.8
516
11.24
516
2
910
7.17
0
7.3
384
7.4
384
7.53
384
7.6
418
7.6
418
7.65
418
8.2
452
8.8
452
9.33
452
9.9
516
10.6
516
11.17
516
2
911
5.69
0
5.9
384
6.1
384
6.23
384
6.4
418
6.7
418
6.87
418
7.3
452
7.6
452
8.01
452
8.6
516
9.3
516
9.9
516
2
938
6.68
0
6.9
384
7.2
384
7.48
384
7.9
418
8.3
418
8.68
418
9.1
452
9.5
452
9.87
452
10.2
516
10.6
516
10.9
516
3
909
6.58
0
7.0
973
7.4
973
7.83
973
8.1
1078
8.4
1078
8.74
1078
9.1
1183
9.4
1183
9.76
1183
10.3
1319
10.9
1319
11.51
1319
3
912
6.69
0
7.0
973
7.4
973
7.73
973
8.2
1078
8.7
1078
9.17
1078
9.4
1183
9.6
1183
9.85
1183
10.4
1319
10.9
1319
11.49
1319
3
925
7.35
0
7.6
973
7.8
973
8.03
973
8.2
1078
8.3
1078
8.41
1078
8.9
1183
9.5
1183
10.02
1183
10.5
1319
10.9
1319
11.31
1319
3
936
6.52
0
6.7
973
6.8
973
6.92
973
7.1
1078
7.3
1078
7.54
1078
7.9
1183
8.2
1183
8.57
1183
9.1
1319
9.6
1319
10.05
1319
4
918
6.46
0
6.7
289
7.0
289
7.25
289
7.7
325
8.2
325
8.67
325
8.9
367
9.1
367
9.31
367
9.8
398
10.3
398
10.85
398
4
929
8.11
0
8.4
289
8.6
289
8.86
289
9.2
325
9.6
325
10.01
325
10.2
367
10.4
367
10.55
367
11.1
398
11.6
398
12.12
398
4
932
6.35
0
6.8
289
7.3
289
7.79
289
8.1
325
8.3
325
8.57
325
8.9
367
9.3
367
9.64
367
10.1
398
10.6
398
11.11
398
4
937
6.04
0
6.3
289
6.6
289
6.87
289
7.3
325
7.7
325
8.05
325
8.4
367
8.7
367
9.05
367
9.7
398
10.3
398
10.96
398
5
913
6.04
0
6.3
752
6.6
752
6.92
752
7.3
848
7.7
848
8.07
848
8.4
935
8.7
935
8.99
935
9.4
1025
9.9
1025
10.32
1025
5
914
6.93
0
7.3
752
7.7
752
8.14
752
8.5
848
8.9
848
9.22
848
9.4
467
9.5
935
9.71
935
10.5
1025
11.2
1025
11.93
922
5
919
6.34
0
6.6
752
6.8
752
7.06
752
7.3
848
7.5
848
7.74
848
8.1
935
8.5
935
8.85
935
9.3
1025
9.7
1025
10.19
1025
5
939
8.86
0
9.3
752
9.7
752
10.2
752
10.4
848
10.7
848
10.96
848
11.4
935
11.8
935
12.29
935
12.8
1025
13.2
1025
13.67
1025
6
901
6.83
0
7.2
337
7.5
337
7.8
337
8.1
374
8.3
374
8.61
374
8.9
413
9.3
413
9.58
413
10.1
456
10.6
456
11.13
456
6
922
6.24
0
6.5
337
6.8
337
7.02
337
7.4
374
7.7
374
8.06
374
8.4
413
8.8
413
9.12
413
9.6
456
10.1
456
10.59
456
6
930
7.38
0
7.6
337
7.9
337
8.11
337
8.4
374
8.7
374
9.06
374
9.3
413
9.5
413
9.74
413
10.3
456
10.9
456
11.43
456
6
933
8.4
0
8.8
337
9.1
337
9.47
337
9.8
374
10.1
374
10.45
374
10.9
413
11.4
413
11.94
413
12.2
456
12.5
456
12.75
456
7
915
6.67
0
7.0
844
7.4
844
7.77
844
8.1
983
8.4
983
8.75
983
9.1
1070
9.4
1070
9.67
1070
10.2
1150
10.7
1150
11.25
1150
7
921
8.43
0
8.8
844
9.1
844
9.41
633
9.8
860
10.2
983
10.6
983
10.8
1070
11.0
1070
11.2
1070
11.8
1150
12.3
1150
12.92
1150
7
924
6.5
0
7.2
844
7.8
844
8.48
844
8.7
983
8.9
983
9.1
983
9.4
1070
9.6
1070
9.88
1070
10.4
1150
10.8
1150
11.3
1150
7
934
7.26
0
7.7
844
8.2
844
8.65
844
8.9
983
9.1
983
9.25
983
9.5
1070
9.8
1070
10.05
1070
10.5
1150
11.0
1150
11.54
1150
8
905
6.5
0
6.9
265
7.3
265
7.77
265
8.0
300
8.3
300
8.59
300
8.8
335
9.0
335
9.22
335
9.9
355
10.5
355
11.15
355
8
917
7.93
0
8.2
265
8.5
265
8.78
265
9.4
300
9.9
300
10.5
300
10.6
335
10.7
335
10.82
335
10.8
355
10.8
355
10.77
355
8
920
6.8
0
7.3
265
7.8
265
8.31
265
8.6
300
8.9
300
9.12
300
9.4
335
9.6
335
9.85
335
10.4
355
10.9
355
11.37
355
8
927
7.43
0
7.7
265
7.9
265
8.11
265
8.5
300
8.8
300
9.18
300
9.4
335
9.7
335
9.89
335
10.7
355
11.6
355
12.38
355
9
904
6.2
0
6.7
614
7.2
614
7.65
614
7.9
692
8.2
692
8.41
692
8.8
783
9.2
783
9.61
783
10.3
843
10.9
843
11.61
843
9
908
7
0
7.3
614
7.6
614
7.85
614
8.3
692
8.8
692
9.27
692
9.4
783
9.6
783
9.71
783
10.3
843
10.8
843
11.39
843
9
926
6.39
0
6.5
614
6.7
614
6.82
614
7.2
692
7.6
692
7.97
692
8.1
783
8.2
783
8.27
783
8.8
843
9.4
738
9.93
738
9
931
6.71
0
7.1
614
7.5
614
7.84
614
8.2
692
8.6
692
9
692
9.3
783
9.7
783
10.02
783
10.5
843
10.9
843
11.32
843
Day 2 - Pig 921 did not eat entire afternoon dose (ate approximately 50%). Daily dose adjusted to 75%
Day 3 - Pig 921 did not eat entire morning dose (ate approximately 75%). Daily dose adjusted to 87.5%.
Day 6 - Pig 914 did not eat one dose. Daily dose adjusted to 50%.
Day 10 - Pig 926 did not eat entire morning dose (ate approximately 75%). Daily dose adjusted to 87.5%.
Day 11 - Pig 914 did not eat entire morning dose (ate approximately 80%). Daily dose adjusted to 90%.
Day 11 - Pig 926 did not eat entire morning dose (ate approximately 75%). Daily dose adjusted to 87.5%.
VB2urinemast.xls
-------
TABLE C-2
Body Weight Adjusted Doses
(Dose for Day/BW for Day)
Group
ID#
Day 0
Day 1
Day 2
Day 3
Day 4
Day 5
Day 6
Day 7
Day 8
Day 9
Day 10
Day 11
Avg Dos Target Dosi % Target
Avg %
1
903
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0
1
935
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0
1
940
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0
2
902
51.18
49.03
47.04
49.58
48.10
46.70
48.52
46.67
44.95
49.37
47.56
45.89
47.88
50
96
2
910
52.66
51.80
50.98
55.15
54.86
54.58
55.02
51.51
48.42
51.87
48.86
46.17
51.82
50
104
2
911
65.40
63.45
61.62
64.80
62.72
60.77
62.31
59.21
56.40
59.69
55.64
52.10
60.34
50
121
2
938
55.26
53.22
51.32
52.98
50.42
48.10
49.77
47.69
45.77
50.50
48.86
47.32
50.10
50
100
105
3
909
139.08
131.27
124.28
132.59
127.83
123.39
130.30
125.60
121.22
127.50
120.69
114.57
126.53
125
101
3
912
138.29
131.80
125.89
131.36
124.10
117.60
125.91
122.94
120.11
126.84
120.51
114.77
125.01
125
100
3
925
128.44
124.71
121.19
132.22
130.19
128.23
132.24
124.76
118.08
126.20
121.21
116.60
125.34
125
100
3
936
146.26
143.39
140.63
151.32
147.06
143.03
150.08
143.82
138.05
145.50
137.99
131.22
143.20
125
115
104
4
918
43.05
41.43
39.92
42.09
39.66
37.49
41.36
40.39
39.47
40.50
38.48
36.66
40.04
50
80
4
929
34.62
33.62
32.67
35.17
33.77
32.47
36.06
35.43
34.83
35.92
34.30
32.82
34.31
50
69
4
932
42.38
39.60
37.16
40.38
39.12
37.93
41.16
39.58
38.11
39.27
37.46
35.81
39.00
50
78
4
937
45.82
43.90
42.13
44.75
42.46
40.38
43.83
42.15
40.60
41.07
38.53
36.30
41.83
50
84
78
5
913
118.72
113.47
108.66
116.17
110.38
105.13
111.58
107.64
103.97
108.62
103.75
99.29
108.95
125
87
5
914
102.53
97.19
92.37
99.82
95.76
92.02
49.81
97.91
96.26
98.05
91.57
77.30
90.88
125
73
5
919
114.27
110.25
106.50
116.44
112.92
109.62
115.25
110.22
105.61
110.22
105.17
100.56
109.75
125
88
5
939
80.85
77.20
73.86
81.27
79.29
77.41
81.97
78.90
76.05
80.37
77.57
74.96
78.31
125
63
78
6
901
47.15
45.11
43.24
46.31
44.81
43.41
46.18
44.57
43.06
45.13
42.94
40.94
44.41
50
89
6
922
51.89
49.90
48.05
50.74
48.46
46.37
49.04
47.06
45.24
47.42
45.12
43.03
47.69
50
95
6
930
44.25
42.88
41.59
44.35
42.75
41.25
44.43
43.37
42.36
44.23
41.93
39.87
42.77
50
86
6
933
38.52
37.01
35.62
38.15
36.92
35.77
37.69
36.05
34.55
37.32
36.51
35.74
36.65
50
73
86
7
915
119.87
113.94
108.56
121.46
116.75
112.39
118.19
114.32
110.70
112.78
107.24
102.22
113.20
125
91
7
921
96.33
92.86
67.23
87.74
96.38
92.77
99.11
97.31
95.57
97.68
93.14
89.01
92.10
125
74
7
924
117.81
107.87
99.47
113.21
110.58
108.07
114.36
111.27
108.34
111.08
106.22
101.77
109.17
125
87
7
934
109.22
103.03
97.51
111.12
108.66
106.31
112.48
109.41
106.51
109.04
104.14
99.65
106.42
125
85
84
8
905
38.23
36.02
34.06
37.24
36.02
34.87
38.11
37.22
36.38
35.97
33.76
31.82
35.81
50
72
8
917
32.22
31.15
30.14
32.03
30.18
28.53
31.62
31.31
31.00
32.84
32.89
32.94
31.40
50
63
8
920
36.24
33.90
31.85
34.91
33.85
32.85
35.82
34.91
34.05
34.25
32.66
31.20
33.87
50
68
8
927
34.56
33.57
32.63
35.38
33.95
32.63
35.62
34.74
33.91
33.09
30.71
28.66
33.29
50
67
67
9
904
91.84
85.65
80.24
87.56
84.84
82.28
88.87
85.01
81.47
82.02
77.03
72.60
83.28
125
67
9
908
84.28
81.12
78.19
83.14
78.67
74.65
83.15
81.87
80.63
82.08
77.83
74.00
79.97
125
64
9
926
93.95
91.93
90.00
96.07
91.21
86.83
97.02
95.83
94.67
95.53
78.66
74.28
90.50
125
72
9
931
86.61
82.24
78.29
84.12
80.34
76.89
83.83
80.88
78.14
80.64
77.43
74.46
80.32
125
64
67
Page 1
-------
TABLE C-3 VB Experiment 2 Urine Volumes - 48 hour collections
Units of Volume: ml
Day
Group
Pig ID
-1 to 0*
6-7
8-9
10-11
10/1/99-10/2/99
10/8/99-10/10/99
10/10/99-10/12/99
10/12/99-10/14/99
1
903
800
4700
2240
5240
935
400
1860
2290
4000
940
124
960
430
580
2
902
198
2100
1020
4000
910
126
620
810
800
911
400
560
650
2900
938
142
1320
690
1090
3
909
800
1940
3640
2540
912
1400
4440
2980
3880
925
400
2220
3330
10000
936
800
4260
2920
4600
4
918
2200
10740
10030
12260
929
3200
8600
6750
5860
932
800
4520
4000
8660
937
107
1380
860
880
5
913
400
2220
1820
2000
914
200
1440
1320
1400
919
1200
5300
5420
7440
939
1200
2100
1400
2000
6
901
400
2320
1920
1500
922
1400
2300
2740
2800
930
600
3100
2720
2960
933
800
5640
5140
5040
7
915
1600
5280
6240
5800
921
2000
10540
10160
16000
924
2800
4400
5700
7100
934
2000
5460
3200
4260
8
905
400
1840
1200
1800
917
2000
6220
2600
1660
920
108
660
560
1300
927
600
6840
8360
10420
9
904
800
4360
5540
6400
908
192
2640
1040
3200
926
600
1240
1700
3140
931
2400
3460
2460
4000
Volume measured by:
ZL
CG
CG/TE
MD
Date:
10/2/1999
10/10/1999
10/12/1999
10/14/1999
* 24 hour collection pre-dosing
VB2urinemast.xls
-------
TABLE C-4 URINE ANALYTICAL RESULTS
tag number
pig number
day
group
material administered dosage Q
Urine Cone
Un
VB-02-00056
903
-1
1
Control
0
11
ng/m
VB-02-00063
935
-1
1
Control
0
36
ng/m
VB-02-00037
940
-1
1
Control
0
130
ng/m
VB-02-00032
902
-1
2
NaAs
50
69
ng/m
VB-02-00038
910
-1
2
NaAs
50
41
ng/m
VB-02-00062
911
-1
2
NaAs
50
32
ng/m
VB-02-00036
938
-1
2
NaAs
50
150
ng/m
VB-02-00059
909
-1
3
NaAs
125
34
ng/m
VB-02-00052
912
-1
3
NaAs
125
13
ng/m
VB-02-00039
925
-1
3
NaAs
125
39
ng/m
VB-02-00041
936
-1
3
NaAs
125
11
ng/m
VB-02-00035
918
-1
4
TM4
50
81
ng/m
VB-02-00031
929
-1
4
TM4
50
41
ng/m
VB-02-00053
932
-1
4
TM4
50
22
ng/m
VB-02-00054
937
-1
4
TM4
50
150
ng/m
VB-02-00042
913
-1
5
TM4
125
33
ng/m
VB-02-00051
914
-1
5
TM4
125
68
ng/m
VB-02-00068
919
-1
5
TM4
125
10
ng/m
VB-02-00064
939
-1
5
TM4
125
10
ng/m
VB-02-00044
901
-1
6
TM5
50
51
ng/m
VB-02-00046
922
-1
6
TM5
50
18
ng/m
VB-02-00067
930
-1
6
TM5
50
18
ng/m
VB-02-00050
933
-1
6
TM5
50
29
ng/m
VB-02-00060
915
-1
7
TM5
125
14
ng/m
VB-02-00058
921
-1
7
TM5
125
12
ng/m
VB-02-00055
924
-1
7
TM5
125
9
ng/m
VB-02-00065
934
-1
7
TM5
125
7
ng/m
VB-02-00045
905
-1
8
TM6
50
62
ng/m
VB-02-00040
917
-1
8
TM6
50
4
ng/m
VB-02-00033
920
-1
8
TM6
50
110
ng/m
VB-02-00048
927
-1
8
TM6
50
18
ng/m
VB-02-00061
904
-1
9
TM6
125
10
ng/m
VB-02-00057
908
-1
9
TM6
125
83
ng/m
VB-02-00043
926
-1
9
TM6
125
30
ng/m
VB-02-00047
931
-1
9
TM6
125
4
ng/m
VB-02-00034
2930
-1
6
TM5
50
19
ng/m
VB-02-00066
2926
-1
9
TM6
125
31
ng/m
VB-02-00049
2901
-1
6
TM5
50
53
ng/m
VB-02-00075
903
6/7
1
Control
0
18
ng/m
VB-02-00086
935
6/7
1
Control
0
44
ng/m
VB-02-00102
940
6/7
1
Control
0
77
ng/m
VB-02-00120
902
6/7
2
NaAs
50
o
CO
CO
ng/m
VB-02-00092
910
6/7
2
NaAs
50
1400
ng/m
VB-02-00082
911
6/7
2
NaAs
50
580
ng/m
VB-02-00115
938
6/7
2
NaAs
50
650
ng/m
VB-02-00118
909
6/7
3
NaAs
125
820
ng/m
VB-02-00094
912
6/7
3
NaAs
125
480
ng/m
VB-02-00106
925
6/7
3
NaAs
125
470
ng/m
VB-02-00076
936
6/7
3
NaAs
125
360
ng/m
VB-02-00072
918
6/7
4
TM4
50
14
ng/m
VB2urinemast.xls
-------
| tag number
| pig number
I day
I group
| material administered | dosage|
VB-02-00111
929
6/7
4
TM4
50
VB-02-00077
932
6/7
4
TM4
50
VB-02-00087
937
6/7
4
TM4
50
VB-02-00078
913
6/7
5
TM4
125
VB-02-00097
914
6/7
5
TM4
125
VB-02-00108
919
6/7
5
TM4
125
VB-02-00071
939
6/7
5
TM4
125
VB-02-00093
901
6/7
6
TM5
50
VB-02-00116
922
6/7
6
TM5
50
VB-02-00084
930
6/7
6
TM5
50
VB-02-00074
933
6/7
6
TM5
50
VB-02-00098
915
6/7
7
TM5
125
VB-02-00083
921
6/7
7
TM5
125
VB-02-00073
924
6/7
7
TM5
125
VB-02-00105
934
6/7
7
TM5
125
VB-02-00069
905
6/7
8
TM6
50
VB-02-00100
917
6/7
8
TM6
50
VB-02-00095
920
6/7
8
TM6
50
VB-02-00079
927
6/7
8
TM6
50
VB-02-00103
904
6/7
9
TM6
125
VB-02-00104
908
6/7
9
TM6
125
VB-02-00099
926
6/7
9
TM6
125
VB-02-00081
931
6/7
9
TM6
125
VB-02-00110
2931
6/7
9
TM6
125
VB-02-00089
2925
6/7
3
NaAs
125
VB-02-00101
2902
6/7
2
NaAs
50
VB-02-00121
AsCtrl
6/7
VB-02-00117
AslAlOO
6/7
VB-02-00091
AslBlOO
6/7
VB-02-00114
AsOA100
6/7
VB-02-00107
AsOBlOO
6/7
VB-02-00119
AslA25
6/7
VB-02-00085
AslB25
6/7
VB-02-00090
AsOA25
6/7
VB-02-00113
AsOB25
6/7
VB-02-00096
AslA5
6/7
VB-02-00070
AslB5
6/7
VB-02-00088
AsOA5
6/7
VB-02-00122
AsOB5
6/7
VB-02-00109
AsMixl
6/7
VB-02-00112
AsMix2
6/7
VB-02-00080
AsMix3
6/7
VB-02-00145
903
8/9
1
Control
0
VB-02-00136
935
8/9
1
Control
0
VB-02-00156
940
8/9
1
Control
0
VB-02-00155
902
8/9
2
NaAs
50
VB-02-00163
910
8/9
2
NaAs
50
VB-02-00158
911
8/9
2
NaAs
50
VB-02-00127
938
8/9
2
NaAs
50
VB-02-00167
909
8/9
3
NaAs
125
VB-02-00152
912
8/9
3
NaAs
125
VB-02-00147
925
8/9
3
NaAs
125
Urine Cone |
30
55
120
130
130
91
160
120
93
94
56
55
28
78
66
130
30
290
23
51
130
120
96
100
490
400
17
120
110
80
94
42
41
33
36
21
23
23
22
97
37
20
21
38
220
510
1500
550
1200
570
620
410
Units
ng/mL
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
ng/m
VB2urinemast.xls
-------
tag number
| pig number
I day
I group
| material administered | dosage| Q
| Urine Cone
Uni
VB-02-00159
936
8/9
3
NaAs
125
520
ng/m
VB-02-00168
918
8/9
4
TM4
50
21
ng/m
VB-02-00169
929
8/9
4
TM4
50
42
ng/m
VB-02-00130
932
8/9
4
TM4
50
58
ng/m
VB-02-00160
937
8/9
4
TM4
50
260
ng/m
VB-02-00166
913
8/9
5
TM4
125
150
ng/m
VB-02-00137
914
8/9
5
TM4
125
220
ng/m
VB-02-00125
919
8/9
5
TM4
125
80
ng/m
VB-02-00174
939
8/9
5
TM4
125
210
ng/m
VB-02-00128
901
8/9
6
TM5
50
110
ng/m
VB-02-00134
922
8/9
6
TM5
50
87
ng/m
VB-02-00129
930
8/9
6
TM5
50
76
ng/m
VB-02-00150
933
8/9
6
TM5
50
50
ng/m
VB-02-00175
915
8/9
7
TM5
125
50
ng/m
VB-02-00142
921
8/9
7
TM5
125
40
ng/m
VB-02-00173
924
8/9
7
TM5
125
62
ng/m
VB-02-00148
934
8/9
7
TM5
125
110
ng/m
VB-02-00132
905
8/9
8
TM6
50
190
ng/m
VB-02-00171
917
8/9
8
TM6
50
70
ng/m
VB-02-00157
920
8/9
8
TM6
50
370
ng/m
VB-02-00170
927
8/9
8
TM6
50
25
ng/m
VB-02-00161
904
8/9
9
TM6
125
75
ng/m
VB-02-00138
908
8/9
9
TM6
125
260
ng/m
VB-02-00146
926
8/9
9
TM6
125
170
ng/m
VB-02-00165
931
8/9
9
TM6
125
140
ng/m
VB-02-00126
2936
8/9
3
NaAs
125
500
ng/m
VB-02-00144
2921
8/9
7
TM5
125
40
ng/m
VB-02-00131
2904
8/9
9
TM6
125
75
ng/m
VB-02-00133
AsCtrl
8/9
19
ng/m
VB-02-00153
AslAlOO
8/9
120
ng/m
VB-02-00151
AslBlOO
8/9
120
ng/m
VB-02-00123
AsOA100
8/9
79
ng/m
VB-02-00143
AsOBlOO
8/9
96
ng/m
VB-02-00176
AslA25
8/9
45
ng/m
VB-02-00139
AslB25
8/9
39
ng/m
VB-02-00162
AsOA25
8/9
33
ng/m
VB-02-00124
AsOB25
8/9
36
ng/m
VB-02-00140
AslA5
8/9
23
ng/m
VB-02-00172
AslB5
8/9
23
ng/m
VB-02-00135
AsOA5
8/9
22
ng/m
VB-02-00164
AsOB5
8/9
24
ng/m
VB-02-00149
AsMixl
8/9
37
ng/m
VB-02-00154
AsMix2
8/9
37
ng/m
VB-02-00141
AsMix3
8/9
21
ng/m
VB-02-00212
903
1
1
Control
0
21
ng/m
VB-02-00204
935
1
1
Control
0
38
ng/m
VB-02-00218
940
1
1
Control
0
71
ng/m
VB-02-00184
902
1
2
NaAs
50
200
ng/m
VB-02-00216
910
1
2
NaAs
50
950
ng/m
VB-02-00226
911
1
2
NaAs
50
200
ng/m
VB-02-00203
938
1
2
NaAs
50
670
ng/m
VB2urinemast.xls
-------
tag number
| pig number |
day | group
| material administered | dosage| Q
| Urine Cone
Un
VB-02-00219
909
1 3
NaAs
125
750
ng/m
VB-02-00181
912
1 3
NaAs
125
450
ng/m
VB-02-00194
925
1 3
NaAs
125
180
ng/m
VB-02-00208
936
1 3
NaAs
125
170
ng/m
VB-02-00190
918
1 4
TM4
50
21
ng/m
VB-02-00221
929
1 4
TM4
50
46
ng/m
VB-02-00222
932
1 4
TM4
50
29
ng/m
VB-02-00186
937
1 4
TM4
50
210
ng/m
VB-02-00177
913
1 5
TM4
125
170
ng/m
VB-02-00228
914
1 5
TM4
125
370
ng/m
VB-02-00179
919
1 5
TM4
125
69
ng/m
VB-02-00201
939
1 5
TM4
125
210
ng/m
VB-02-00202
901
1 6
TM5
50
150
ng/m
VB-02-00214
922
1 6
TM5
50
79
ng/m
VB-02-00198
930
1 6
TM5
50
65
ng/m
VB-02-00220
933
1 6
TM5
50
47
ng/m
VB-02-00205
915
1 7
TM5
125
59
ng/m
VB-02-00188
921
1 7
TM5
125
34
ng/m
VB-02-00200
924
1 7
TM5
125
54
ng/m
VB-02-00195
934
1 7
TM5
125
100
ng/m
VB-02-00223
905
1 8
TM6
50
110
ng/m
VB-02-00182
917
1 8
TM6
50
93
ng/m
VB-02-00185
920
1 8
TM6
50
180
ng/m
VB-02-00192
927
1 8
TM6
50
20
ng/m
VB-02-00213
904
1 9
TM6
125
67
ng/m
VB-02-00230
908
1 9
TM6
125
150
ng/m
VB-02-00187
926
1 9
TM6
125
140
ng/m
VB-02-00191
931
1 9
TM6
125
95
ng/m
VB-02-00210
2911
1 2
NaAs
50
190
ng/m
VB-02-00183
2922
1 6
TM5
50
79
ng/m
VB-02-00211
2902
1 2
NaAs
50
210
ng/m
VB-02-00199
AsCtrl
18
ng/m
VB-02-00189
AslAlOO
130
ng/m
VB-02-00206
AslBlOO
120
ng/m
VB-02-00227
AsOA100
83
ng/m
VB-02-00215
AsOBlOO
95
ng/m
VB-02-00207
AslA25
44
ng/m
VB-02-00209
AslB25
42
ng/m
VB-02-00178
AsOA25
33
ng/m
VB-02-00229
AsOB25
38
ng/m
VB-02-00193
AslA5
23
ng/m
VB-02-00180
AslB5
24
ng/m
VB-02-00217
AsOA5
22
ng/m
VB-02-00196
AsOB5
23
ng/m
VB-02-00224
AsMixl
99
ng/m
VB-02-00197
AsMix2
38
ng/m
VB-02-00225
AsMix3
22
ng/m
VB2urinemast.xls
-------
TABLE C-5 VB Experiment 2 Fecal Weights - 48 hour collections
Units of Weight: g
Day
Group
Pig ID
6-7
8-9
10-11
10/8/99-10/10/99
10/10/99-10/12/99
10/12/99-10/14/99
1
903
245.19
266.19
267.9
935
383.48
162.39
159.68
940
192.53
137.66
129.01
2
902
121.91
179.59
248.34
910
169.06
65.98
238.39
911
198.38
189.91
245.14
938
173.4
173.5
157.42
3
909
92.53
179.86
185.08
912
156.18
141.49
209.51
925
191.43
71.26
135.81
936
197.43
241.75
259.44
4
918
223.11
202.48
213.82
929
316.77
304.92
393.77
932
59.55
205.08
187.51
937
83.31
59.4
330.39
5
913
288.48
260.72
357.49
914
442.41
288.52
407.72
919
212.17
266.36
305.39
939
235.19
207.61
215.17
6
901
202.43
240.4
317.85
922
149.62
187.38
184.16
930
214.24
257.42
288.63
933
201.4
189.68
248.28
7
915
146.66
154.33
247.97
921
314.49
219.73
297.13
924
300.09
236.33
141.96
934
323.47
247.98
465.07
8
905
180.79
139.98
165.15
917
299.25
234.58
213.3
920
227.19
225.14
314
927
336.79
205.54
369.78
9
904
326.3
392.19
341.52
908
277.89
221.89
294.4
926
257.14
249.45
503.91
931
237.3
231.63
359.32
Weighed by:
DD
DD
DD
Date:
10/26/1999
10/26/1999
10/26/1999
VB2fecesmast.xls
-------
TABLE C-6 FECES ANALYTICAL RESULTS
tag number
pig number
day
group
material administered dosage Q
Feces Cone Units
VB-02-00250
903
6/7
1
Control
0
160 ng/g ww
VB-02-00243
935
6/7
1
Control
0
89 ng/g ww
VB-02-00261
940
6/7
1
Control
0
100 ng/g ww
VB-02-00256
902
6/7
2
NaAs
50
330 ng/g ww
VB-02-00264
910
6/7
2
NaAs
50
410 ng/g ww
VB-02-00259
911
6/7
2
NaAs
50
310 ng/g ww
VB-02-00267
938
6/7
2
NaAs
50
550 ng/g ww
VB-02-00238
909
6/7
3
NaAs
125
490 ng/g ww
VB-02-00248
912
6/7
3
NaAs
125
530 ng/g ww
VB-02-00231
925
6/7
3
NaAs
125
560 ng/g ww
VB-02-00244
936
6/7
3
NaAs
125
650 ng/g ww
VB-02-00257
918
6/7
4
TM4
50
2400 ng/g ww
VB-02-00233
929
6/7
4
TM4
50
1600 ng/g ww
VB-02-00249
932
6/7
4
TM4
50
2100 ng/g ww
VB-02-00246
937
6/7
4
TM4
50
3100 ng/g ww
VB-02-00254
913
6/7
5
TM4
125
2100 ng/g ww
VB-02-00253
914
6/7
5
TM4
125
1500 ng/g ww
VB-02-00240
919
6/7
5
TM4
125
4300 ng/g ww
VB-02-00268
939
6/7
5
TM4
125
4000 ng/g ww
VB-02-00242
901
6/7
6
TM5
50
2300 ng/g ww
VB-02-00236
922
6/7
6
TM5
50
4100 ng/g ww
VB-02-00252
930
6/7
6
TM5
50
2800 ng/g ww
VB-02-00251
933
6/7
6
TM5
50
3000 ng/g ww
VB-02-00258
915
6/7
7
TM5
125
1100 ng/g ww
VB-02-00235
921
6/7
7
TM5
125
4000 ng/g ww
VB-02-00263
924
6/7
7
TM5
125
4900 ng/g ww
VB-02-00237
934
6/7
7
TM5
125
4200 ng/g ww
VB-02-00232
905
6/7
8
TM6
50
2000 ng/g ww
VB-02-00265
917
6/7
8
TM6
50
920 ng/g ww
VB-02-00266
920
6/7
8
TM6
50
2300 ng/g ww
VB-02-00234
927
6/7
8
TM6
50
730 ng/g ww
VB-02-00255
904
6/7
9
TM6
125
3800 ng/g ww
VB-02-00239
908
6/7
9
TM6
125
5000 ng/g ww
VB-02-00260
926
6/7
9
TM6
125
1200 ng/g ww
VB-02-00241
931
6/7
9
TM6
125
3500 ng/g ww
VB-02-00262
2934
6/7
7
TM5
125
4200 ng/g ww
VB-02-00247
2908
6/7
9
TM6
125
4300 ng/g ww
VB-02-00245
2902
6/7
2
NaAs
50
310 ng/g ww
VB-02-00278
903
8/9
1
Control
0
190 ng/g ww
VB-02-00306
935
8/9
1
Control
0
170 ng/g ww
VB-02-00271
940
8/9
1
Control
0
160 ng/g ww
VB-02-00275
902
8/9
2
NaAs
50
300 ng/g ww
VB-02-00304
910
8/9
2
NaAs
50
620 ng/g ww
VB-02-00294
911
8/9
2
NaAs
50
290 ng/g ww
VB-02-00292
938
8/9
2
NaAs
50
620 ng/g ww
VB-02-00301
909
8/9
3
NaAs
125
620 ng/g ww
VB-02-00296
912
8/9
3
NaAs
125
600 ng/g ww
VB-02-00272
925
8/9
3
NaAs
125
650 ng/g ww
VB-02-00303
936
8/9
3
NaAs
125
910 ng/g ww
VB-02-00279
918
8/9
4
TM4
50
2100 ng/g ww
-------
| tag number
| pig number
I day
I group
| material administered! dosage| Q
| Feces Cone | Units
VB-02-00285
929
8/9
4
TM4
50
1800 ng/g ww
VB-02-00276
932
8/9
4
TM4
50
3400 ng/g ww
VB-02-00299
937
8/9
4
TM4
50
4100 ng/g ww
VB-02-00277
913
8/9
5
TM4
125
3500 ng/g ww
VB-02-00287
914
8/9
5
TM4
125
1800 ng/g ww
VB-02-00291
919
8/9
5
TM4
125
5100 ng/g ww
VB-02-00305
939
8/9
5
TM4
125
3900 ng/g ww
VB-02-00295
901
8/9
6
TM5
50
3000 ng/g ww
VB-02-00288
922
8/9
6
TM5
50
4500 ng/g ww
VB-02-00282
930
8/9
6
TM5
50
2600 ng/g ww
VB-02-00293
933
8/9
6
TM5
50
4500 ng/g ww
VB-02-00290
915
8/9
7
TM5
125
11000 ng/g ww
VB-02-00283
921
8/9
7
TM5
125
5500 ng/g ww
VB-02-00269
924
8/9
7
TM5
125
10000 ng/g ww
VB-02-00297
934
8/9
7
TM5
125
7400 ng/g ww
VB-02-00284
905
8/9
8
TM6
50
7600 ng/g ww
VB-02-00302
917
8/9
8
TM6
50
2000 ng/g ww
VB-02-00298
920
8/9
8
TM6
50
1700 ng/g ww
VB-02-00280
927
8/9
8
TM6
50
1700 ng/g ww
VB-02-00270
904
8/9
9
TM6
125
4600 ng/g ww
VB-02-00286
908
8/9
9
TM6
125
4900 ng/g ww
VB-02-00274
926
8/9
9
TM6
125
2400 ng/g ww
VB-02-00289
931
8/9
9
TM6
125
4300 ng/g ww
VB-02-00300
2901
8/9
6
TM5
50
4700 ng/g ww
VB-02-00273
2913
8/9
5
TM4
125
3600 ng/g ww
VB-02-00281
2920
8/9
8
TM6
50
2500 ng/g ww
VB-02-00312
903
10/11
1
Control
0
160 ng/g ww
VB-02-00307
935
10/11
1
Control
0
170 ng/g ww
VB-02-00334
940
10/11
1
Control
0
330 ng/g ww
VB-02-00332
902
10/11
2
NaAs
50
100 ng/g ww
VB-02-00336
910
10/11
2
NaAs
50
530 ng/g ww
VB-02-00313
911
10/11
2
NaAs
50
320 ng/g ww
VB-02-00344
938
10/11
2
NaAs
50
530 ng/g ww
VB-02-00321
909
10/11
3
NaAs
125
650 ng/g ww
VB-02-00320
912
10/11
3
NaAs
125
570 ng/g ww
VB-02-00331
925
10/11
3
NaAs
125
810 ng/g ww
VB-02-00324
936
10/11
3
NaAs
125
1600 ng/g ww
VB-02-00333
918
10/11
4
TM4
50
2400 ng/g ww
VB-02-00319
929
10/11
4
TM4
50
1200 ng/g ww
VB-02-00317
932
10/11
4
TM4
50
3100 ng/g ww
VB-02-00325
937
10/11
4
TM4
50
1900 ng/g ww
VB-02-00339
913
10/11
5
TM4
125
2700 ng/g ww
VB-02-00329
914
10/11
5
TM4
125
2600 ng/g ww
VB-02-00328
919
10/11
5
TM4
125
4700 ng/g ww
VB-02-00330
939
10/11
5
TM4
125
5500 ng/g ww
VB-02-00341
901
10/11
6
TM5
50
2400 ng/g ww
VB-02-00342
922
10/11
6
TM5
50
3900 ng/g ww
VB-02-00308
930
10/11
6
TM5
50
2200 ng/g ww
VB-02-00314
933
10/11
6
TM5
50
2600 ng/g ww
VB-02-00316
915
10/11
7
TM5
125
4400 ng/g ww
VB-02-00323
921
10/11
7
TM5
125
6000 ng/g ww
VB-02-00326
924
10/11
7
TM5
125
4200 ng/g ww
-------
| tag number
| pig number
I day
I group
| material administered! dosage| Q
| Feces Cone | Units
VB-02-00343
934
10/11
7
TM5
125
6200 ng/g ww
VB-02-00340
905
10/11
8
TM6
50
2700 ng/g ww
VB-02-00337
917
10/11
8
TM6
50
1500 ng/g ww
VB-02-00327
920
10/11
8
TM6
50
2300 ng/g ww
VB-02-00310
927
10/11
8
TM6
50
1400 ng/g ww
VB-02-00335
904
10/11
9
TM6
125
3700 ng/g ww
VB-02-00338
908
10/11
9
TM6
125
3800 ng/g ww
VB-02-00318
926
10/11
9
TM6
125
3500 ng/g ww
VB-02-00315
931
10/11
9
TM6
125
3600 ng/g ww
VB-02-00309
2922
10/11
6
TM5
50
4100 ng/g ww
VB-02-00322
2918
10/11
4
TM4
50
1900 ng/g ww
VB-02-00311
2927
10/11
8
TM6
50
1400 ng/g ww
-------
FIGURE 4-11 RELATION BETWEEN URINARY AND FECAL EXCRETION
LU
FEF vs UEF revised.xls
-------
FIGURE 4-12 In Vivo RBA vs In Vitro BA
0.8 -i—
0.7 -
0.6 -
0.5 -
<
go 0.4 -
0.3 -
0.2 -
0.1 -
0.0 —
0.0
y = 0.8122x + 0.0502
R2 = 0.6445
~~
0.1
0.2
0.3
0.4
RBA
0.5
0.6
0.7
0.8
In vitro results revised.xls
------- |